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Abstract
Chronic and acute dietary exposure to pyrrolizidine alkaloids (PAs) was estimated in the European
population via the consumption of plant-derived foods. This resulted in highest estimates of mean
chronic dietary exposure of 34.5–48.4 ng/kg body weight (bw) per day in ‘Toddlers’ (LB–UB) and
154–214 ng/kg bw per day in the highly exposed population (LB–UB, also in ‘Toddlers’). Following a
rather conservative scenario, the highest estimates of acute mean exposure and 95th percentile
exposure were calculated for ‘Toddlers’, with mean exposure up to 311 ng/kg bw per day and 95th
percentile exposure up to 821 ng/kg bw per day. Tea and herbal infusions were by far the main
average contributors to the total exposure to PAs. Among consumers only, in the adult population, the
mean chronic exposure via the consumption of honey ranged between 0.1 and 7.4 ng/kg bw per day
(minimum LB–maximum UB), while for high consumers, it was between 0.4 and 18 ng/kg bw per day
(minimum LB–maximum UB). In the young population, for the average consumers of honey, estimates
were between 0.3 and 27 ng/kg bw per day (minimum LB–maximum UB), and between 0.7 and
31 ng/kg bw per day (minimum LB–maximum UB) among the high consumers. Ad hoc exposure
scenarios for food supplements via consumption of pollen-based supplements showed chronic
exposure to PAs that ranged between 0.7 and 12 ng/kg bw per day (minimum LB–maximum UB),
while acute exposure was between 2.8 and 44 ng/kg bw per day (minimum LB–maximum UB), in both
cases among consumers only. Likewise, the consumption of 150 mL infusion of 2 g of selected plant
extracts led to exposures to PAs up to 67,000 ng/kg bw per day (e.g. infusion of Borage).
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Summary
Pyrrolizidine alkaloids (PAs) are plant secondary metabolites against herbivores. More than 6,000
plant species are known to biosynthesise PAs, mainly from the botanical families of the Boraginaceae
(e.g. Heliotropium spp.), Asteraceae (e.g. Senecio spp.) and Fabaceae (e.g. Crotalaria spp.).
Nowadays, about 600 PAs have been identiﬁed. Many PAs can be present both as their free base and
as N-oxides, which can be converted to the free base in humans and animals.
The toxicity of PAs depends mainly on the nature of the bond in position 1,2 of the pyrrolizidine
ring system. The toxicity of PAs in humans is well known from various poisoning cases following
ingestion of PAs containing herbal medicines and teas. Only limited data in experimental animals are
available, mostly on 1,2-unsaturated PAs. The available information indicates that the adverse effects
of 1,2-unsaturated PAs in experimental animals include hepatotoxicity, developmental toxicity,
genotoxicity and carcinogenicity. Based on that the EFSA Panel on Contaminants in the Food Chain
(CONTAM) decided, in its scientiﬁc opinion in 2011 on PAs in food and feed, to focus on the risk
assessment of 1,2-unsaturated PAs and their respective N-oxide forms. A Margin of Exposure (MOE)
approach for genotoxic carcinogens to the sum of 1,2-unsaturated PAs was adopted, assuming equal
potency. The Panel derived a benchmark dose lower conﬁdence limit for a 10% excess cancer risk
(BMDL10) of 70 lg/kg body weight (bw) per day for induction of liver haemangiosarcomas by
lasiocarpine in male rats, and selected it as the reference point for the assessment of chronic risks. In
addition, in this scientiﬁc opinion, the EFSA CONTAM Panel also selected a lowest known PA dose
associated with acute/short-term toxicity in humans of approximately 2 mg/kg bw per day for the
assessment of acute risks.
Based on the outcome of the EFSA 2011 opinion on pyrrolizidine alkaloids (PAs) and two projects
aimed at monitoring PAs in different foods, and considering the available analytical standards, the
European Commission provisionally selected 28 PAs as relevant in food samples: echimidine,
echimidine-N-oxide, heliotrine, heliotrine-N-oxide, lycopsamine, lycopsamine-N-oxide, intermedine,
intermedine-N-oxide, erucifoline, erucifoline-N-oxide, senecionine, senecionine-N-oxide, seneci
(o)phylline, seneciphylline-N-oxide, monocrotaline, monocrotaline-N-oxide, jacobine, jacobine-N-oxide,
senecivernine, senecivernine-N-oxide, retrorsine, retrorsine-N-oxide, europine, europine-N-oxide,
lasiocarpine, lasiocarpine-N-oxide, senkirkine and trichodesmine.
Considering the relevant 28 PAs provisionally selected, and after applying diverse data cleaning and
validation steps, a ﬁnal data set of 4,581 food samples of plant origin was available for exposure
estimations (among them 1,966 on retail honey, and 2,307 on tea and herbal infusions). A total of 825
food samples of animal origin were not considered for the dietary exposure estimations, since for 97%
of these samples all analysed PAs were reported as left-censored data and for the rest PAs were
present at relatively low levels. The total content of PAs in each food sample was estimated adding up
the reported amount for each individual PA analysed. To avoid underestimation on the presence of
PAs, only those samples with a minimum number of PAs were included in the ﬁnal data set; this
number was selected after a comprehensive evaluation of the occurrence data in each type of food
commodity.
The ﬁnal data set of retail honey samples was composed of the 1,324 samples already used in the
2011 EFSA opinion (with a common set of 8 PAs) together with those samples recently submitted that
contain at least lycopsamine, echimidine and senecionine. The number of PAs per sample varied
between 8 and 19. Retail honey unspeciﬁed (as usually reported in the consumption database, 94.5%
of the eating occasions) contained PA concentrations of 14.5–27.5 lg/kg (lower bound–upper bound
(LB–UB)). Among the samples of retail honey, the main average contributors to the total PA
concentration were echimidine (44%) and lycopsamine (37%).
The ﬁnal data set of tea and herbal infusions contained samples of, among others, ‘Tea and herbs
for infusions, unspeciﬁed’ (n = 1,002), ‘Black tea, infusion’ (n = 339), ‘Green tea, infusion’ (n = 310),
‘Camomile ﬂowers’ (n = 256), Peppermint (n = 196) and ‘Rooibos’ (n = 167). The number of PAs
analysed per sample in the ﬁnal data set ranged between 17 and 28. Taking into account the ﬁnal data
set, among the samples of green tea, the main contributors, on average, to the total PA concentration
were senecionine-N-oxide (19%), retrorsine-N-oxide (18%), and intermedine and lycopsamine, both
with 16% contribution. In black tea, the main contributors, on average, were intermedine-N-oxide
(31%), intermedine (20%), lycopsamine (20%) and retrorsine-N-oxide (15%), in camomile
senecionine-N-oxide (28%), intermedine (22%), senecionine and lycopsamine (both 10%), in
peppermint seneciphylline-N-oxide (28%), senecionine-N-oxide (25%), retrorsine-N-oxide (13%) and
seneci(o)phylline (11%), and in rooibos, senecionine-N-oxide (57%), retrorsine-N-oxide (19%) and
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senecionine (14%). The highest average concentrations of PAs (expressed as consumed) were found
in the samples of rooibos (LB = 4.1 lg/L) and peppermint (LB = 3.5 lg/L). Concentrations of PAs in
black tea were twice as high as reported for green tea (LB = 1.6 lg/L and LB = 0.8 lg/L,
respectively). An apparent downward trend was noted in the levels of PAs in tea and herbal infusions,
based on some of the most recently reported levels as compared with the data reported in previous
years. This is observed, in particular, at the LB scenario, indicating that this trend may be inﬂuenced
by the lack of sensitivity of the analytical methods.
Very high levels of PA were reported for certain food supplements. Pollen-based supplements
reported average PA concentrations of 235–253 lg/kg (LB–UB); much higher concentrations were
reported for some plant extracts consumed as infusions such as Borage (Borago ofﬁcinalis) with levels
up to 2,332,558 lg/kg or up to 419,309 lg/kg in Coltsfoot (Tussilago farfara). Likewise, other
supplements containing plant material sold as capsules/tablets, to be directly ingested, also reported
very high levels of PAs (hemp-agrimony (Eupatorium cannabinum) up to 2,410,275 lg/kg).
In order to cover the whole range of concentrations of PAs reported for tea and herbal infusions,
the estimation of dietary exposure to PAs considered two different scenarios. Together with the other
food commodities, a ﬁrst scenario considered all the samples of tea and herbal infusions submitted by
the national authorities and those collected through an EFSA Article 36 grant, while a second scenario
assessed exposure based on samples of tea and herbal infusions submitted by Tea & Herbal Infusions
Europe (THIE).
Chronic and acute dietary exposure to PAs was estimated via the consumption of foods of plant
origin, particularly tea, herbal infusions and honey. Speciﬁc scenarios considering only consumers were
used to estimate exposure to PAs and to identify possible risks among small subgroups of the
population consuming speciﬁc commodities (e.g. honey, rooibos, etc.).
Considering all food commodities, and the data on tea and herbal infusions submitted by the EU
Member States (MSs) and through an EFSA Article 36 grant, the highest estimates of mean chronic
dietary exposure to PAs in the young population (‘Infants’, ‘Toddlers’ and ‘Other children’) were
34.5–48.4 ng/kg bw per day (LB–UB), and 31.1–41.8 ng/kg bw per day (LB–UB) in the adult
population (‘Adults’, ‘Elderly’, ‘Very elderly’). In the highly exposed population, the highest estimates
were 153.8–214 ng/kg bw per day and 87.7–127.2 ng/kg bw per day (LB–UB) in the young and the
adult population, respectively. When using the data on tea and herbal infusions submitted by
THIE, the estimates of chronic exposure were lower as compared with the previous scenario. The
highest estimates of mean chronic dietary exposure to PAs in the young population (LB–UB) were
6.1–29.8 ng/kg bw per day and 5.7–33.4 ng/kg bw per day in the adult population. In the highly
exposed population, the highest estimates were 23.3–131.6 ng/kg bw per day and 15.9–78.8 ng/kg
bw per day (LB–UB) in the young and the adult population, respectively. Overall, in ‘Infants’ and
‘Toddlers’ the main average contributors to the chronic dietary exposure to PAs were either ‘Tea,
unspeciﬁed’ or ‘Tea and herbs for infusions, unspeciﬁed’. In the adult population, the main contributor
to the chronic exposure to PAs was tea, either reported as ‘Tea, unspeciﬁed’ or as ‘Black tea, infusion’.
Among consumers only, in the adult population, the mean chronic exposure via the consumption of
honey, ranged between 0.1 and 7.4 ng/kg bw per day (minimum LB–maximum UB), while for high
consumers (95th percentile exposure), it was between 0.4 and 17.6 ng/kg bw per day (minimum
LB–maximum UB). Higher exposure was estimated among the consumers of honey in the young
population. For the average consumers, estimates oscillated between 0.3 and 27 ng/kg bw per day
(minimum LB–maximum UB), and between 0.7 and 31.1 ng/kg bw per day (minimum LB–maximum
UB) among the high consumers.
Acute dietary exposure to PAs was estimated following a conservative approach considering the
presence of high contamination levels in all the different food commodities (occurrence values at the
highest reliable percentile, UB estimate), combined with the total daily consumption amount for each
corresponding food and adding up all consumed foods (consuming days only). The highest estimates of
acute mean exposure and 95th percentile exposure were calculated for ‘Toddlers’, with mean exposure
to PAs up to 311 ng/kg bw per day and 95th percentile exposure up to 821 ng/kg bw per day.
The consumption of 150 mL infusion of 2 g of selected plant extracts (dilution factor 1/75 as used
for tea and herbal infusions) can lead to exposures to PAs from 800 ng/kg bw per day for one infusion
of mix herbs (among them Pulmonaria ofﬁcinalis) to 67,000 ng/kg bw per day for one infusion of
Borage (B. ofﬁcinalis). Chronic exposure to PAs via consumption of pollen-based supplements ranged
between 0.7 and 11.5 ng/kg bw per day (minimum LB–maximum UB), while the acute exposure
was between 2.8 and 43.9 ng/kg bw per day (minimum LB–maximum UB) in both cases among
consumers only.
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On estimating dietary exposure to 28 PAs, the UB scenario is highly inﬂuenced by the sensitivity of
the analytical methods. Based on the current sensitivity of the reported analytical methods, lowest
UB concentrations of 53 lg/kg (0.7 lg/L) can be achieved for tea and herbal infusions. This implies
mean chronic exposure levels up to 6.1–21 ng/kg bw per day, and up to 14.6–28.3 ng/kg bw per day
among the highly exposed consumers (adult–young population), depending on the tea and herbal
infusion consumed.
For honey, the lowest UB concentration reported with all eight PAs at levels below the limit of
quantiﬁcation (LOQ) would be 3.6 lg/kg. This would lead to mean chronic exposure estimations up to
3.5 ng/kg bw per day and up to 4.1 ng/kg bw per day among the highly exposed consumers.
Different sources of uncertainty in the estimation of the dietary exposure to PAs were identiﬁed.
Among others, the most important refer to the large proportion of left-censored data, the fact that not
all samples reported analytical data for all 28 PAs, and to the presence of an important number of
both eating occasions and occurrence data on unspeciﬁed tea and herbs for infusions. Likewise,
uncertainty is also associated with how accurately the concentration of PAs reported in the samples of
tea and herbal infusions represents the amounts of contaminants the consumers are exposed to.
Different methods are used to extract the PAs present in tea and herbal infusions prior to their
analysis, and there is uncertainty on how these methods represent the different ways consumers
prepare tea and herbal infusions. In addition, many different factors, such as water temperature,
water-to-tea ratio, infusion time, stirring and dosage form (loose leaf and tea bag), may have an
inﬂuence on the extraction of PAs during consumer preparation. Overall, the dietary exposure to PAs
calculated in this report is likely to overestimate the exposure levels of the European population.
In order to reduce UB levels, it is recommended to develop more sensitive analytical methods and
deﬁne performance criteria for the analysis of the most relevant PAs in food. Efforts should continue to
collect analytical data on the occurrence of PAs in relevant food commodities, but in particular on tea
and herbal infusions to conﬁrm the downward trend in PA levels on the most recently reported
samples. Data on the presence of PAs in herbal food supplements other than plant extracts should be
also collected. Further investigation should be done on the weeds responsible of the presence of PAs
in tea and herbal infusions, as well as to develop adequate measures to control weed infestation.
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1. Introduction
Pyrrolizidine alkaloids (PAs) are plant secondary metabolites against herbivores. More than 6,000
plant species are known to biosynthesise PAs, mainly from the botanical families of the Boraginaceae
(e.g. Heliotropium spp.), Asteraceae (e.g. Senecio spp.) and Fabaceae (e.g. Crotalaria spp.) (Smith and
Culvenor, 1981).
Figure 1 shows the most important structural features of PAs. From a chemical standpoint, this
class of alkaloids is characterised by the presence of a pyrrolizidine ring system (1,2,3,6,7,8-hexahydro-
5H-pyrrolizine), which is the basic structure of various 1-hydroxymethyl derivatives called necines or
necine bases (for a comprehensive overview see Mattocks, 1986; Hartmann and Witte, 1995; Roeder,
1999). The diversity of the various necine bases is attributable to three features:
• the presence of a double bond in position 1,2 resulting in the 1,2-unsaturated PA class of
higher toxicological relevance;
• the presence of an additional hydroxy group in position 7, allowing for the formation of open-
or cyclic diesters;
• the N-methylation of the pyrrolizidine ring, hindering the conversion to N-oxide (PANO)
derivatives.
The rich variety of PAs results from a series of combinations of the various necine bases with a pool
of different mono- or dicarboxylic acids (necic acids) to form monoesters, and open- or cyclic diesters.
Nowadays, about 600 PAs have been identiﬁed. Many PAs can be present both as their free base and
as N-oxides, which can be converted to the free base in humans and animals.
The toxicity of PAs depends mainly on the nature of the bond in position 1,2 of the pyrrolizidine
ring system. Cytochrome P-450 mediated metabolism of 1,2-unsaturated PAs can form pyrroles
(dihydropyrrolizine (DHP) and DHP esters), which can readily react with proteins and form DNA
adducts (Fu et al., 2004; Wang et al., 2005). Conversely, 1,2-saturated PAs cannot form such
reactive metabolites.
The toxicity of PAs in humans is well known from various poisoning cases following ingestion of PA
containing herbal medicines and teas, and outbreak cases including deaths associated with the
consumption of grain contaminated with PA containing weeds (see e.g. WHO-IPCS, 1988; Prakash et al.,
1999; Kakar et al., 2010; Bane et al., 2012; Schneider et al., 2012), with liver and lung as the main
target organs. The acute/short-term toxicity of 1,2-unsaturated PAs in humans is characterised mainly
by the onset of hepatic veno-occlusive disease (HVOD), associated with high mortality and, or possibly
progressing to liver cirrhosis. In its 2011 scientiﬁc opinion on the presence of PAs in food and feed, from
the evaluation of various human case reports, the EFSA Panel on Contaminants in the Food Chain
(CONTAM Panel) selected a lowest known PA dose associated with acute/short-term toxicity in humans
of approximately 2 mg/kg bw per day for the assessment of acute risks (EFSA CONTAM Panel, 2011).
Only limited data in experimental animals are available, mostly on 1,2-unsaturated PAs. The
available information indicates that the adverse effects of 1,2-unsaturated PAs in experimental animals
include hepatotoxicity, developmental toxicity, genotoxicity and carcinogenicity. The formation of
N N
OHR
R = H or -OH
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e.g. 9-hydroxy 1-methylpyrrolizidine
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Figure 1: Structural features of PAs. (A) core structural motif pyrrolizidine (1,2,3,6,7,8-hexahydro-5H-
pyrrolizine); (B) general description of the main necine base parts of naturally occurring PAs
including the common necine base numbering; (C) necine base otonecine; a core structural
motif of otonecine-type PAs; (D) general pyrrolizine structure motif and (E) structural example
of 1,2-unsaturated ester PA senecionine (Figure taken from EFSA CONTAM Panel, 2011)
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reactive pyrroles is considered to be the key step related to all the identiﬁed adverse effects (Fu et al.,
2004). Therefore, the CONTAM Panel decided to focus on the risk assessment of 1,2-unsaturated PAs
and their respective N-oxide forms (EFSA CONTAM Panel, 2011). Considering that all 1,2-unsaturated
PAs share a common metabolic pathway leading to the formation of genotoxic and carcinogenic
reactive pyrroles, the CONTAM Panel concluded that it was not appropriate to establish a health-based
guidance value, and decided to adopt the Margin of Exposure (MOE) approach for genotoxic
carcinogens to the sum of 1,2-unsaturated PAs, assuming equal potency. The Panel derived a
benchmark dose lower conﬁdence limit for a 10% excess cancer risk (BMDL10) of 70 lg/kg body
weight (bw) per day for induction of liver haemangiosarcomas by lasiocarpine in male rats, and
selected it as the reference point for the assessment of chronic risks.
The dietary exposure assessment of the CONTAM Panel 2011 opinion was limited to honey as
occurrence data were only available for this food product (EFSA CONTAM Panel, 2011). Two data sets
were submitted to EFSA, which included testing of 14 and 17 PAs, respectively, with eight PAs in
common between the two data sets. The two data sets included results both from samples of retail
honey, that is mostly blended and ready for consumption, and bulk honey which was used by the
CONTAM Panel to cover the scenario of honey purchased locally from a single source. For retail honey,
chronic exposure levels up to 37.4 ng/kg bw per day and 9.03 ng/kg bw per day were estimated for
children and adults (mean consumption in honey consumers only), respectively. Chronic exposure up
to 77.8 ng/kg bw per day and 26 ng/kg bw per day were estimated for the two age groups for 95th
percentile consumption in children and adults, respectively. Acute exposure levels up to 254 ng/kg bw
and 110 ng/kg bw were estimated considering the 95th PAs concentrations and 95th single day
consumption for children and adults, respectively. The theoretical exposure calculated for consumption
of unblended (bulk) honey was in general about 50–100% higher than the results of the calculations
for retail honey. Then CONTAM Panel identiﬁed also PAs of particular importance for food and feed,
considering the prominent alkaloids present in the main known PA containing plants (EFSA CONTAM
Panel, 2011). The list of PAs of particular importance for food and feed identiﬁed by the CONTAM
Panel (EFSA CONTAM Panel, 2011) was subsequently taken forward by the European Commission in a
recommendation for monitoring PAs in food (SCOFCAH, 2014), although it was noted at the time that
analytical standards were available only for some of the PAs listed in the European Food Safety
Authority (EFSA) opinion. Short after, two projects aimed at monitoring PAs in different foods were
performed. One project was carried out by the Federal Institute for Risk Assessment (BfR, 2013), while
the second one was a project delivered as a result of an Article 36 grant (GP/EFSA/CONTAM/2013/03)
awarded by EFSA to a consortium led by RIKILT and composed also by the Federal Institute for Risk
Assessment (BfR) and the Institute for Research and Technology in Food and Agriculture (IRTA). The
results of this project were published as an EFSA external Scientiﬁc report (Mulder et al., 2015). Based
on the outcome of the EFSA 2011 opinion and these two reports, considering the available analytical
standards, the European Commission provisionally selected 28 PAs as relevant in food samples
(see Table 1).
Regarding the project carried out by BfR, 17 PAs were monitored for which analytical standards
were available, in herbal infusions and teas, including two PAs (intermedine and senkirkine) not
identiﬁed as of particular importance in the EFSA 2011 opinion (BfR, 2013). In the external Scientiﬁc
report of EFSA (Mulder et al., 2015), analytical standards for 39 PAs were identiﬁed. In the project,
validated analytical methods were set up for 35 PAs in food of animal origins, and 28 PAs in plant-
derived food. The 28 PAs monitored in the plant-derived food included the 17 PAs monitored by BfR in
2013. Out of these 28 PAs, ﬁve (intermedine, intermedine-N-oxide, senecivernine, senecivernine-N-
oxide and senkirkine) were not identiﬁed as of particular importance in honey by the EFSA CONTAM
Panel (EFSA CONTAM Panel, 2011). However, two out of the 28 PAs analysed (indicine and
intermedine) co-eluted under the chromatographic conditions used by the beneﬁciaries of the EFSA
grant. The list of PAs included in the EFSA external scientiﬁc report for the monitoring of plant-derived
food (Mulder et al., 2015) is shown in Table 1.
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Maximum levels (ML) for PAs in food are not established in Commission Regulation (EC) No 1881/2006
setting MLs for certain contaminants in foodstuffs.
1.1. Background and Terms of Reference as provided by the European
Commission
Following the outcome of EFSA’s scientiﬁc opinion on pyrrolizidine alkaloids in food and feed in 2011
and the availability of new occurrence data on the presence of pyrrolizidine alkaloids in food, the
Commission is considering the possible setting of maximum levels of pyrrolizidine alkaloids in honey,
tea, herbal infusions, herbs and food supplements. The exposure assessment in the scientiﬁc opinion
was only related to the consumption of honey as only occurrence data on pyrrolizidine alkaloids in
honey were at that time available. In the meantime data in tea, herbal infusions and food supplements
have become available. It would therefore be appropriate to have an updated exposure assessment
available (also taking into account the updated comprehensive food consumption database). Given that
there are some very high levels of pyrrolizidine alkaloids found in certain samples of honey, tea, herbal
infusions and food supplements, it is also appropriate to estimate the changes in exposure by applying
speciﬁc cut-off levels (not taking into account the data with levels above a certain cut-off value).
In accordance with Art. 31 (1) of Regulation (EC) No 178/2002 the Commission asks EFSA for a
dietary exposure assessment to pyrrolizidine alkaloids in honey, tea, herbal infusions (herbs) and food
supplements taking into account:
• occurrence data available in the EFSA database;
• updated comprehensive food consumption database;
• changes in estimated dietary exposure by applying speciﬁc cut-off values.
2. Data and methodologies
2.1. Data
2.1.1. Occurrence data
2.1.1.1. Data collection and validation
At the moment of the preparation of this scientiﬁc report, following the ofﬁcial request from the
European Commission (January 2016), a total of 378,752 analytical results on 87 different pyrrolizidine
alkaloids (PAs) were available in the EFSA Chemical Occurrence database, among them 345,107
Table 1: List of the 28 PAs provisionally selected by the European Commission as relevant in food
samples
CAS number CAS number
Echimidine 520-68-3 Lycopsamine 10285-07-1
Echimidine-N-oxide 41093-89-4 Lycopsamine-N-oxide 95462-15-0
Erucifoline 40158-95-0 Monocrotaline 315-22-0
Erucifoline-N-oxide 123864-94-8 Monocrotaline-N-oxide 35337-98-5
Europine 570-19-4 Retrorsine 480-54-6
Europine-N-oxide 65582-53-8 Retrorsine-N-oxide 15503-86-3
Heliotrine 303-33-3 Seneci(o)phylline 480-81-9
Heliotrine-N-oxide 6209-65-0 Seneciphylline-N-oxide 38710-26-8
Intermedine 10285-06-0 Senecionine 130-01-8
Intermedine-N-oxide 95462-14-9 Senecionine-N-oxide 13268-67-2
Jacobine 6870-67-3 Senecivernine 72755-25-0
Jacobine-N-oxide 38710-25-7 Senecivernine-N-oxide 101687-28-9
Lasiocarpine 303-34-4 Senkirkine 2318-18-5
Lasiocarpine-N-oxide 127-30-0 Trichodesmine 548-90-3
CAS: Chemical Abstracts Service.
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corresponding to food samples and the rest to feed (33,645). As regards food samples, a total of 274,632
analytical results belonged to the 28 PAS provisionally selected by the European Commission for the
analysis of PAs in food (listed in Table 1). The concentration of PAs in each food sample was estimated
adding up all the individual levels of PAs analysed among the 28 selected by the European Commission.
The data were submitted to EFSA following the requirements of the EFSA Guidance on Standard
Sample Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the
EFSA standard operating procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of
food consumption and occurrence data’.
2.1.1.2. Data analysis
Following the EFSA SOP on ‘Data analysis and reporting’ to guarantee an appropriate quality of the
data used in the exposure assessment, the initial data set was carefully evaluated applying several
data cleaning and validation steps. Special attention was paid to the number of PAs reported in each
sample as well as to different parameters, such as ‘Analytical method’, ‘Reporting unit’ and the
codiﬁcation of the different food samples under the FoodEx classiﬁcation. The outcome of the data
analysis is shown in Section 3.
Analytical results were all submitted on a whole weight basis (lg/kg). The left-censored data were
treated by the substitution method as recommended in the ‘Principles and Methods for the Risk
Assessment of Chemicals in Food’ (WHO/IPCS, 2009). The same method is indicated in the EFSA
scientiﬁc report ‘Management of left-censored data in dietary exposure assessment of chemical
substances’ (EFSA, 2010b) as an option in the treatment of left-censored data. The guidance suggests
that the lower-bound (LB) and upper-bound (UB) approach should be used for chemicals likely to be
present in the food (e.g. naturally occurring contaminants, nutrients and mycotoxins). At the LB,
results below the limit of quantiﬁcation (LOQ) and limit of detection (LOD) were replaced by zero; at
the UB, the results below the LOD were replaced by the LOD and those below the LOQ were replaced
by the value reported as LOQ. Additionally, as a point estimate between the two extremes, the middle
bound (MB) scenario was calculated by assigning a value of LOD/2 or LOQ/2 to the left-censored data.
2.1.2. Consumption data
2.1.2.1. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest
version of the Comprehensive Database1 contains results from a total of 51 different dietary surveys
carried out in 23 different EU Member States (MSs) covering 94,532 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as described in Table 2;
two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (Latvia)
and ‘Lactating women’ (Greece).
For chronic exposure assessment, food consumption data were available from 44 different dietary
surveys carried out in 19 different European countries. Seven additional dietary surveys with only
1 day per subject from seven different countries (covering all age classes except infants) were
available for acute exposure assessment. Overall, the food consumption data gathered by EFSA in the
Table 2: Age classes considered in the EFSA Comprehensive European Food Consumption Database
Age range
Infants < 12 months old
Toddlers ≥ 12 months to < 36 months old
Other children ≥ 36 months to < 10 years old
Adolescents ≥ 10 years to < 18 years old
Adults ≥ 18 years to < 65 years old
Elderly ≥ 65 years to < 75 years old
Very elderly ≥ 75 years old
1 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb
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Comprehensive Database are the most complete and detailed data currently available in the European
Union (EU). Consumption data were collected using single or repeated 24- or 48-h dietary recalls, and
dietary records covering from 3 to 7 days per subject. Owing to the differences in the methods used
for data collection, direct country-to-country comparisons can be misleading.
2.1.3. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food groups (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800
end-points (food names or generic food names) at the fourth level.
For the classiﬁcation of tea and herbal infusions, the FoodEx classiﬁcation allows the possibility to
codify the samples as solid (‘Tea and herbs for infusions’, Level 2) or as consumed (‘Tea, infusion’,
Level 2). In order to better describe the reported data and to obtain more accurate dietary exposure
estimations, tea and herbal infusions were codiﬁed using the category that best matched the food
commodity.
2.2. Methodologies
2.2.1. Dietary exposure assessment
2.2.1.1. Dietary exposure assessment in humans
Based on the outcome of the 2011 EFSA Scientiﬁc opinion on PAs both acute and chronic exposure
were assessed. As suggested by the EFSA Working Group on Food Consumption and Exposure, dietary
surveys with only 1 day per subject were considered for acute exposure as they are not adequate to
assess repeated exposure (EFSA, 2011a). Similarly, subjects who participated only 1 day in the dietary
studies, when the protocol prescribed more reporting days per individual, were also excluded for the
chronic exposure assessment. Thus, for chronic exposure assessment, food consumption data were
used from 35 different and most recent dietary surveys carried out in 19 different European countries
present in the latest version of the Comprehensive Database.
For calculating chronic dietary exposure to PAs, food consumption and body weight data at the
individual level were accessed in the Comprehensive Database. Occurrence data and consumption data
were linked at the lowest FoodEx level possible. In addition, the different food commodities were
grouped within each food category to better explain their contribution to the total dietary exposure to
PAs. Exposure estimates were calculated for each dietary survey and age class. The mean and the
high (95th percentile) chronic dietary exposures were calculated by combining PAs mean occurrence
values with the average daily consumption for each food at individual level in each dietary survey.
Acute dietary exposure to PAs in the general population was estimated following a rather
conservative approach considering the presence of high contamination levels in the different food
commodities (occurrence values at the highest reliable percentile), combined with the total daily
consumption amount for each corresponding food and adding up all consumed foods (consuming days
only). A total of 41 most recent dietary surveys carried out in 23 different European countries were used.
In Appendix A, the number of available days for each age class used in the acute exposure
assessment is described beside the number of subjects available for the chronic exposure assessment.
Speciﬁc exposure scenarios (chronic and acute) for selected food commodities were also assessed
in order to better understand the exposure to PAs in the European population. Table 3 shows all the
different exposure scenarios considered in this scientiﬁc report to estimate dietary exposure to PAs.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1).
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3. Assessment
3.1. Pyrrolizidine alkaloid occurrence in food
As commented in the previous sections, this scientiﬁc report focuses on the 28 PAs provisionally
selected by the European Commission. This selections is based on the 2011 EFSA scientiﬁc opinion
where only occurrence data on honey were available (EFSA CONTAM Panel, 2011), and two recent
research projects that identiﬁed key PAs in tea and herbal infusions (BfR, 2013; Mulder et al., 2015).
The list of the 28 selected PAs is shown in Table 1 and covers the following PAs: echimidine,
echimidine-N-oxide, heliotrine, heliotrine-N-oxide, lycopsamine, lycopsamine-N-oxide, intermedine,
intermedine-N-oxide, erucifoline, erucifoline-N-oxide, senecionine, senecionine-N-oxide, seneci
(o)phylline, seneciphylline-N-oxide, monocrotaline, monocrotaline-N-oxide, jacobine, jacobine-N-oxide,
senecivernine, senecivernine-N-oxide, retrorsine, retrorsine-N-oxide, europine, europine-N-oxide,
lasiocarpine, lasiocarpine-N-oxide, senkirkine and trichodesmine.
Considering the relevant 28 PAs, an initial number of 274,632 analytical results on PAs in food
samples were available, accounting for a total of 19,332 food samples. Among these samples, the
number of PAs analysed per sample ranged between one (n = 29) and 28 (n = 761). As mentioned in
Section 2.1.1, the occurrence data were carefully analysed before being used to estimate dietary
exposure. The total content of PAs in each food commodity was estimated adding up the reported
amount for each individual PA analysed. In order to avoid underestimation on the presence of PA, only
those samples with a minimum number of PAs were selected; this number is discussed for the
different food categories in the relevant sections.
Special attention was also paid to the presence of two additional PAs that could be relevant due to
their toxicity, riddelliine and riddelliine-N-oxide. Both of them are found in different Senecio plants,
with riddelliine deﬁned by the International Agency for Research on Cancer (IARC) as possibly
carcinogenic to humans (Group 2B). These two PAs were analysed in 301 samples of tea and herbal
infusions, and in all cases were reported below the LOQ. For riddelliine, the LOQs ranged between
5 lg/kg and 50 lg/kg; for riddelliine-N-oxide, LOQs ranged between 5 lg/kg and 20 lg/kg.
Food samples mainly belonged to the food group ‘Honey’ (n = 15,528, FoodEx level 2). A total of
1,722 samples were initially codiﬁed as ‘Tea and herbs for infusion’ (FoodEx level 2), with most
of them codiﬁed as ‘Tea and herbs for infusions, unspeciﬁed’ that covers a very heterogeneous group
of samples that includes mix of herbal infusions, mix of tea and herbal infusions, unspeciﬁed herbal
infusions, and herbal infusions that could not be classiﬁed under FoodEx. A total of 294 samples of
‘Food supplements’, mainly corresponding to diverse types of ‘Plant extract formula’ (n = 216, FoodEx
level 3), were also available.
In addition to honey samples, other 825 food samples of animal origin were also part of this data
set, with 97% of them having all analysed PAs as left-censored data. Previous studies have
demonstrated that, in general, the levels of PAs in animal-derived food are much lower than those that
can be found in food commodities such as tea and herbal infusions. The recent report published by
Mulder et al., 2015, revealed that among 746 samples of animal origin only occasional low levels of
Table 3: Different scenarios used to estimate chronic and acute dietary exposures to PAs
Dietary exposure scenarios
A. Chronic exposure
assessments
A.1. Chronic dietary exposure in the general population (Section 4.1.1 and 4.1.2)
A.2. Chronic dietary exposure, honey consumers only (Section 4.1.3)
A.3. Chronic dietary exposure, tea and herbal infusion consumers only (Section 4.1.3)
A.4. Chronic dietary exposure at selected PA concentrations (Section 4.3)
Honey consumers only
Tea and herbal infusion consumers only
A.5. Chronic dietary exposure to pollen-based supplements (Section 4.4)
B. Acute exposure
assessments
B.1. Acute dietary exposure, consumption days only (Section 4.2)
B.2. Acute dietary exposure to plant extracts(a) (Section 4.3)
B.3. Acute dietary exposure to pollen-based supplements (Section 4.4)
(a): Since only few consumption data on plant extracts were available, this scenario estimates dietary exposure to PAs via the
consumption of particular plant extracts using a single consumption of 150 mL infusion of 2 g of plant extract (dilution factor
1/75 as used for tea and herbal teas).
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PAs in milk samples (6%) were found, mostly with single PAs (i.e. jacoline, senkirkine, otosenine,
lycopsamine, echimidine, retrorsine) in their free base form. Except for two egg samples, PAs were
absent in the milk products, eggs, meat and liver samples analysed.
3.1.1. Honey
Honey samples were reported as bulk honey (13,280 samples) and retail honey (2,248 samples).
Retail honey is considered as mostly blended, ready for consumption and therefore, representative of
what it is habitually consumed. Following the same approach as in the 2011 EFSA opinion, only samples
of retail honey were considered to estimate dietary exposure to PAs (EFSA CONTAM Panel, 2011).
Table 4 shows the number of times that the selected 28 PAs were analysed in the different samples
of retail honey. Most of the retail honey samples had in common eight different PAs (echimidine,
echimidine-N-oxide, heliotrine, lycopsamine, retrorsine, senecionine, seneci(o)phylline and senkirkine).
These eight PAs seems to represent around 75–90% of the total PA levels measured in honey, with
echimidine-N-oxide having minor contribution (EFSA CONTAM Panel, 2011). Among the samples with
these eight PAs, there are 1,324 samples (codiﬁed as ‘Honey, unspeciﬁed’) that were already available
in the 2011 EFSA opinion (EFSA CONTAM Panel, 2011); they correspond to two different data sets
reported separately, one of 1,116 samples (with eight PAs) and another one of 208 (with 14 PAs).
Among the 924 honey samples received after the 2011 EFSA opinion, the number of PAs reported
per sample varied between 1 and 25. In 634 of these samples, the eight PAs mentioned above were
all analysed, except echimidine-N-oxide. In the samples where at least one PA was quantiﬁed, the
most important PAs were lycopsamine (average contribution of 37%), echimidine (average contribution
of 33%) and senecionine (average contribution of 10%). Other PAs that seem to be important in the
total concentration of PAs in honey are intermedine (average contribution of 9.5%) and europine
(average contribution of 8%).
Considering all samples of retail honey as shown in Table 5, the number of PAs analysed went from
a minimum of one PA (one sample) to a maximum of 25 PAs (116 samples), with eight PAs being the
most habitual number of PAs analysed (1,117 samples).
The ﬁnal data set of retail honey samples used for exposure estimations was composed of the
1,324 samples already used in the 2011 EFSA opinion, together with samples recently submitted that
were analysed for at least lycopsamine, echimidine and senecionine. Based on this, a total number of
1,966 samples of honey were used to estimate dietary exposure to PAs. The ﬁnal data set for honey
contains analytical data on 24 different PAs, with a number of PAs per sample varying between a
minimum of eight (n = 1,116) and a maximum of 19 (n = 105).
Table 4: Number of times (N) the selected 28 PAs were analysed in the 2,248 retail honey samples,
and the percentage being left-censored data (LC %)
N LC % N LC % N LC %
Senecionine 2,245 80.8 Senecionine-N-oxide 989 95.4 Trichodesmine 224 98.2
Seneci
(o)phylline
2,245 86.4 Seneciphylline-N-oxide 989 96.3 Jacobine 170 89.4
Senkirkine 2,243 96.8 Retrorsine-N-oxide 966 98.6 Erucifoline 170 94.7
Retrorsine 2,222 87.9 Lasiocarpine 977 98.1 Erucifoline-N-oxide 169 89.3
Heliotrine 2,198 98.2 Monocrotaline 758 98.8 Europine 169 88.2
Lycopsamine 2,073 57.2 Heliotrine-N-oxide 519 99.6 Europine-N-oxide 169 92.3
Echimidine 2,114 48.2 Monocrotaline-N-oxide 400 93.5 Senecivernine 116 82.8
Echimidine-
N-oxide
1,324 99.3 Lycopsamine-N-oxide 316 97.5 Jacobine-N-oxide 116 100
Lasiocarpine-N-oxide 311 99.7 Senecivernine-N-oxide 116 99.1
Intermedine 310 83.5 Intermedine-N-oxide 116 96.6
Pyrrolizidine alkaloids exposure assessment
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2016;14(8):4572
Looking at Table 6, it can be seen the average contribution of each of the PAs analysed in the total
PA concentration for the 1,966 samples of honey. Echimidine (44%) and lycopsamine (37%) were, by
far, the most important PAs in terms of contribution to the levels of PAs in honey.
Table 7 shows the PAs levels estimated in diverse types of retail honey in the ﬁnal data set. Only
for comparison purposes the samples of bulk honey are also included in this table although they were
not used to estimate dietary exposure to PAs. It can be seen that, overall, the average levels of PAs in
bulk honey were more than twofold the levels in retail honey.
Most of the samples of honey were analysed by liquid chromatography–tandem mass spectrometry
(LC–MS/MS) and high-performance liquid chromatography–hydride generation–atomic ﬂuorescence
spectrometry detection (LC–HG–AFS). For LC–MS/MS, the minimum LOQ was reported for echimidine
(0.18 lg/kg), while a maximum LOQ of 7.5 lg/kg was reported for several PAs (retrorsine, retrorsine-
N-oxide and senecionine-N-oxide). The use of LC–HG–AFS allowed higher sensitivity than LC–MS/MS; a
minimum LOQ of 0.05 lg/kg was submitted for all PAS except for intermedine and lycopsamine. For
most of the PAs, the maximum LOQ was 0.3 lg/kg although for particular ones, such as retrorsine and
seneci(o)phylline, the maximum LOQ was 10 lg/kg.
Table 5: Number of PAs analysed in samples of bulk honey and different types of retail honey. Bulk
honey and samples of retail honey not analysed for lycopsamine, echimidine and
senecionine (the three PAs together) were excluded from the ﬁnal data set
Number of pyrrolizidine alkaloids analysed in each sample
Total
1 2 5 8 9 10 11 12 13 14 16 17 18 19 25
Bulk
honey
0 0 0 4,897 0 0 0 0 0 8,383 0 0 0 0 0 13,280
Retail honey
Honey,
unspeciﬁed
0 0 38 1,116 3 17 4 75 3 208 6 18 0 0 16 1,504
Honey,
monoﬂoral
1 1 7 1 46 41 7 134 34 0 13 11 2 48 35 381
Honey,
polyﬂoral
0 0 2 0 72 14 1 31 14 0 13 23 0 31 5 206
Honey,
blended
0 0 0 0 0 0 0 0 0 0 0 0 0 24 57 81
Honeydew
honey
0 0 0 0 1 9 2 38 10 0 2 2 0 2 1 67
Comb
honey
0 0 1 0 0 3 0 2 1 0 0 0 0 0 2 9
PA: pyrrolizidine alkaloids.
Table 6: Average contribution of different PAs to the total PA concentration in the samples of honey
included in the ﬁnal data set
Average
contribution (%)
Average
contribution (%)
Echimidine 43.6 Lycopsamine 37.3
Echimidine-N-oxide 0.1 Lycopsamine-N-oxide 0.0
Erucifoline 0.1 Monocrotaline 0.1
Erucifoline-N-oxide 0.0 Monocrotaline-N-oxide 0.0
Europine 6.7 Retrorsine 3.9
Europine-N-oxide 0.0 Retrorsine-N-oxide 0.4
Heliotrine 0.7 seneci(o)phylline 4.4
Heliotrine-N-oxide 0.0 Senecionine 7.4
Intermedine 8.9 Senecionine-N-oxide 0.7
Jacobine 1.1 Seneciphylline-N-oxide 0.3
Lasiocarpine 0.7 Senkirkine 0.9
Lasiocarpine-N-oxide 0.0 Trichodesmine 0.0
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3.1.2. Tea and herbal infusions
After the evaluation of the samples, a total of 2,374 samples of tea and different herbal infusions
were initially available for dietary exposure estimations. Among them, 1,722 were codiﬁed at FoodEx
level 2 as ‘Tea and herbs for infusions’. Within this food category, the most important group was the
one containing unspeciﬁed herbal infusions and fruit teas (n = 1,040), accompanied by camomile
(n = 269), peppermint (n = 205) and rooibos (n = 168).
Regarding the samples of tea, a total of 14 samples were codiﬁed as ‘Tea, unspeciﬁed’, that
corresponded to samples reported without specifying whether they referred to green or black tea, and
12 were codiﬁed as ‘Tea, decaffeinated’. Together with them, a total of 649 samples corresponded to
either black or green tea, and were classiﬁed as ‘Black tea, infusion’ or ‘Green tea, infusion’,
respectively. Samples of white tea, a non-fermented or lightly fermented tea were classiﬁed as ‘Green
tea, infusion’, while few samples of oolong tea, often described as semi-fermented tea, were classiﬁed
as ‘Black tea, infusion’.
For most of the samples, the concentration of PAs was submitted in lg/kg, referring to the dry
product; in these cases the concentration of PAs was divided by a factor of 75 to obtain the
concentration in the product as consumed (lg/L). This factor was selected based on the protocol used
in the EFSA external scientiﬁc report (Mulder et al., 2015) where the samples of tea and herbal
infusions were prepared according to the standard protocol speciﬁed in the DIN standard 10809 (2 g
of dried plant material in 150 mL boiling water).
Table 7: Levels of PAs (lg/kg) in different types of retail honey. Bulk honey is only included for
comparison purposes
N(a) %LC(b)
PAs
analysed
Variable(c) Mean
Percentiles(d),(e)
P5 P25 Median P75 P95
Retail honey
Honey,
unspeciﬁed
1,429 24 8–17 LB 14.5 0.0 2.0 8.0 20.0 55.0
MB 21.0 6.5 8.5 14.5 25.5 59.0
UB 27.5 13.0 17.0 22.0 31.0 64.0
Honey,
monoﬂoral
275 63 9–19 LB 5.0 0.0 0.0 0.0 2.5 17.6
MB 11.3 4.0 6.5 7.0 9.6 22.5
UB 17.6 6.4 13.0 14.0 17.4 26.8
Honey,
polyﬂoral
183 45 9–19 LB 7.3 0.0 0.0 1.3 6.0 39.9
MB 14.1 6.5 8.5 9.6 11.5 44.4
UB 20.9 10.5 14.8 17.4 19.3 47.5
Honey,
blended
24 46 9–19 LB 14.7 0.0 0.0 0.3 14.0
MB 17.2 2.8 2.8 3.0 16.0
UB 19.8 5.7 5.7 5.7 17.9
Honeydew
honey
52 60 11–19 LB 8.7 0.0 0.0 0.0 15.0 –
MB 14.4 6.4 6.5 7.0 19.5 –
UB 20.1 10.9 13.0 14.0 24.0 –
Comb
honey
3 67 12–13 LB 1.0 – – – – –
MB 7.5 – – – – –
UB 14.0 – – – – –
Bulk honey 13,280 33 8–14 LB 33.3 0.0 0.0 7.0 32.0 144.0
MB 39.7 7.0 8.5 13.0 37.5 149.0
UB 46.1 14.0 17.0 20.0 43.0 154.0
PA: pyrrolizidine alkaloids.
(a): Number of samples.
(b): LC = samples with all PA analysed reported as left-censored data.
(c): LB: lower bound; MB: middle bound; UB: upper bound.
(d): P5/P25/75/95: 5th/25th/75th/95th percentiles.
(e): The estimation of high percentiles is not reliable when too few observations are available (less than 11 for the P75, 29 for
the P90, 60 for the P95 and 298 for the P99).
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Table 8 shows the number of PAs submitted for each of the 2,374 samples of tea and different
herbal infusions initially available. It can be seen that the number of PAs per sample varied between
one (for 28 samples) and 28 PAs (for 386 samples). It is important to mention that for some samples
diverse PAs that could not be chromatographically separated were provided as one analytical result.
Further details for these speciﬁc cases are given later in the report.
Based on two recent research projects that identiﬁed key PAs in tea and herbal infusions (BfR,
2013; Mulder et al., 2015), all the samples for which less than 17 individual PAs were reported were
excluded from the ﬁnal data set, except four samples that reported 16 PAs + two co-eluting PAs.
Likewise, three samples codiﬁed as ‘Ginseng root (Panax ginseng)’ and three as ‘Instant tea, powder’
with all PAs as left-censored data were also excluded.
At the end, a total of 2,307 samples of tea and herbal infusions were available to estimate dietary
exposure to PAs with the number of PAs in each sample ranging from 17 to 28. Some samples of ‘Tea
for infants and young children’ (n = 39) were also available; either 17 or 19 PAs were submitted for
these samples (Table 9). The highest average concentrations of PAs were found in the samples of
rooibos (LB = 4.1 lg/L) and peppermint (LB = 3.5 lg/L). Concentrations of PAs in black tea were
twice as high as reported for green tea (LB = 1.6 lg/L and LB = 0.8 lg/L, respectively). An additional
table with the levels of PAs in the 2,307 samples of tea and herbal infusions expressed as lg/kg in the
dry product is shown in Appendix B.
The data on tea and herbal infusions were submitted by seven different data providers. Five data
sets were submitted by national authorities from the diverse MSs (MS1-DS–MS4-DS), while one data
set (Art36-DS) was the result of Article 36 grant (GP/EFSA/CONTAM/2013/03) awarded by EFSA to a
consortium led by RIKILT and composed also by the Federal Institute for Risk Assessment (BfR) and
the Institute for Research and Technology in Food and Agriculture (IRTA) (Mulder et al., 2015). A
seventh data set (DS-THIE) was provided by Tea & Herbal Infusions Europe (THIE), the European
association representing the interests of producers and traders of tea (Camellia sinensis) and herbal
infusions.
For the data set MS2A-DS, the samples of tea and herbal infusions were all collected between 2010
and 2013, in the data sets MS2B-DS and MS3-DS in 2014, in the data sets MS1-DS and MS4-DS in
2015 and in the data set Art36-DS between 2014 and 2015. For the samples submitted by THIE, they
were collected in two different years, 2015 and 2016.
Table 10 shows the concentration of PAs reported for the different samples of tea and herbal
infusions grouped by data providers. The number of PAs per sample in each data set was different.
Two data sets reported the 28 PAs for each sample (MS4-DS and Art36-DS), one reported 19 PAs per
sample (MS3-DS) and two reported 17 PAs (MS2A-DS and MS2B-DS), while for the samples provided
by THIE, the number of individual PAs varied between 16 and 28. For the data set Art36-DS, baseline
Table 8: Number of individual PAs reported as analysed in samples of tea and herbal infusions
Number of pyrrolizidine alkaloids analysed in each sample
Total
1 2 6 11 12 16 17 18 19 21 22 23 24 25 26 27 28
Tea and herbs for
infusions,
unspeciﬁed
28 0 1 5 2 6 141 12 43 2 11 83 77 15 423 106 85 1,040
Tea, unspeciﬁed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 14
Tea, decaffeinated 0 0 0 0 0 0 0 0 5 0 2 0 3 0 1 1 0 12
Black tea 0 0 0 0 0 0 27 3 40 0 0 1 129 3 7 40 89 339
Green tea 0 0 0 0 0 0 14 23 7 2 0 2 162 2 20 12 68 310
Instant tea, powder 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 3
Camomile 0 0 2 1 0 10 65 0 5 0 41 11 22 1 48 4 59 269
Peppermint 0 1 0 0 0 8 39 2 5 0 4 6 22 13 60 6 39 205
Rooibos 0 0 0 1 0 0 36 1 6 0 0 11 43 4 25 11 30 168
Ginseng 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 3
Yerba mate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 3
Hibiscus 0 0 0 0 0 0 0 1 2 0 0 0 0 0 1 2 0 6
Rose petals 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1
Lime 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
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Table 9: Levels of PAs in the product as consumed (lg/L) in different types of tea and herbal
infusions, together with samples of ‘Tea for infants and young children’
N(a) %LC(b)
PAs
analysed
Variable(c) Mean
Percentiles(d),(e)
P5 P25 Median P75 P95
Tea and herbal infusions
Tea and herbs
for infusions,
unspeciﬁed
1,002 56 16–28 LB 1.8 0.0 0.0 0.0 0.8 5.4
MB 3.4 0.9 1.7 1.9 3.1 6.4
UB 5.1 1.8 3.5 3.6 5.1 7.7
Tea, unspeciﬁed 14 50 28 LB 0.9 – 0.0 0.1 0.6 –
MB 3.9 – 3.1 3.2 3.1 –
UB 6.9 – 6.1 6.2 6.1 –
Tea, decaffeinated 12 58 19–27 LB 0.2 – 0.0 0.0 0.2 –
MB 1.2 – 0.7 1.0 1.7 –
UB 2.3 – 1.3 1.5 3.5 –
Black tea, infusion 339 55 17–28 LB 1.6 0.0 0.0 0.0 0.5 7.6
MB 2.9 0.7 1.2 1.7 2.4 8.9
UB 4.2 1.3 2.0 3.5 3.8 10.3
Green tea, infusion 310 73 17–28 LB 0.8 0.0 0.0 0.0 0.2 3.7
MB 2.3 0.6 1.7 1.7 2.3 4.2
UB 3.8 0.8 3.3 3.5 3.8 6.1
Camomile ﬂowers 256 38 17–28 LB 2.3 0.0 0.0 0.4 2.2 9.8
MB 3.5 0.3 1.5 2.0 3.9 10.4
UB 4.8 0.5 2.8 3.6 5.8 11.2
Peppermint 196 36 17–28 LB 3.5 0.0 0.0 0.4 1.6 10.2
MB 4.9 0.7 1.8 2.0 3.1 11.0
UB 6.2 1.3 2.9 3.6 5.0 11.8
Hibiscus ﬂowers 6 83 18–27 LB 0.0 – – 0.0 – –
MB 2.0 – – 2.4 – –
UB 4.1 – – 4.8 – –
Rose petals 1 100 22 LB 0.0 – – – – –
MB 1.5 – – – – –
UB 2.9 – – – – –
Lime (linden) 1 100 18 LB 0.0 – – – – –
MB 3.0 – – – – –
UB 5.9 – – – – –
Rooibos leaves 167 9 17–28 LB 4.1 0.0 1.1 2.3 4.4 10.3
MB 5.2 0.7 2.2 3.7 5.4 10.6
UB 6.3 1.2 3.6 5.1 6.6 11.3
Yerba mate 3 33 26–28 LB 0.4 – – – – –
MB 2.2 – – – – –
UB 3.9 – – – – –
Tea for infants and
young children
39 26 17–19 LB 0.6 – 0.0 0.2 0.9 –
MB 1.0 – 0.1 0.8 1.6 –
UB 1.4 – 0.2 1.2 2.2 –
(a): Number of samples.
(b): LC = samples with all PA analysed reported as left-censored data.
(c): LB: lower bound; MB: middle bound; UB: upper bound.
(d): P5/P25/75/95: 5th/25th/75th/95th percentiles.
(e): The estimation of high percentiles is not reliable when too few observations are available (less than 11 for the P75, 29 for
the P90, 60 for the P95 and 298 for the P99).
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separation between indicine and intermedine as well as their respective N-oxides was not possible,
although analytical results were submitted either as intermedine or intermedine-N-oxide. This means
that in case of a positive ﬁnding of intermedine, it could be that indicine or a mixture of indicine and
intermedine is present in the samples; the same applies to indicine-N-oxide and intermedine-N-oxide.
The data set DS-THIE also contained diverse co-elutions of two-three PAs when all 28 PAs were not
reported individually (intermedine/lycopsamine, intermedine/lycopsamine-indicine, intermedine-N-
oxide/lycopsamine-N-oxide, intermedine-N-oxide/lycopsamine-N-oxide/indicine-N-oxide, senecionine/
senecivernine, senecionine-N-oxide/senecivernine-N-oxide, indicine-N-oxide/lycopsamine-N-oxide).
MS1-DS contains samples analysed for a total of 18 individual PAs together with six additional PAs that
co-eluted in pairs (jacobine-N-oxide/retrorsine-N-oxide, senecionine-N-oxide/senecivernine-N-oxide,
senecionine/senecivernine). Analytical results reported as co-elutions were also used to estimate the
total concentration of PAs per sample. Overall, the highest number of individual PAs reported was 26
(n = 586 samples) followed by 24 (n = 458 samples).
The average contribution of each individual PA to the total PA concentration for each sample of tea
and herbal infusions in the ﬁnal data set was also assessed (Table 11). The average contribution of
each PA was estimated in those samples where the PA was analysed and at least one PA was
quantiﬁed. Although some uncertainty may be associated to these estimations as not all the samples
were analysed for the 28 PAs, similar results in terms of main contributors to the total PA
concentration were obtained when assessing only the samples analysed for the 28 PAs. Looking at this
table, it can be seen that the identity of the PAs with the highest contributions was slightly different
depending on the food commodity, although some of the PAs were main average contributors in
several teas and herbal infusions. Taking into account the ﬁnal data set, among the samples of green
tea, the main average contributors to the total PA concentration were senecionine-N-oxide (19%),
retrorsine-N-oxide (18%), and intermedine and lycopsamine, both with 16% contribution. A similar
proﬁle was observed for black tea, although intermedine-N-oxide gains importance reaching an
average contribution of 31%. Among the samples of camomile, senecionine-N-oxide and intermedine
were the main average contributors, with 28% and 22%, respectively, followed by senecionine and
lycopsamine, both with 10%. In the herbal infusion peppermint, the main average contributors to the
total PA concentration were seneciphylline-N-oxide (28%) followed by senecionine-N-oxide (25%),
retrorsine-N-oxide (13%) and seneci(o)phylline (11%). In the samples of rooibos, the concentration of
PAs seems to be clearly dominated by senecionine-N-oxide that represents, as an average, 57% of the
total concentration, followed by retrorsine-N-oxide (19%) and senecionine (14%). It should be noted
that for as many as 15 PAs their average contributions to the total concentration of PAs were below
5%, in many cases even below 1%: senecivernine, senecivernine-N-oxide, monocrotaline,
monocrotaline-N-oxide, jacobine, jacobine-N-oxide, lasiocarpine, lasiocarpine-N-oxide, erucifoline,
erucifoline-N-oxide, trichodesmine, europine, senkirkine, heliotrine, and retrorsine. The three last PAs
are included among the typical 8 PAs analysed in honey, although apart from retrorsine the
contribution of senkirkine and heliotrine to the total concentration of PAs is almost negligible (EFSA
CONTAM Panel, 2011). When adding up the average contribution of these 15 PAs in different teas and
herbal infusions, they contributed on average 8% (in samples of peppermint) to 14% (in samples of
green tea) of the total PA concentration.
Supplementary electronic information in Appendix E is provided showing the contribution of the main
eight PAs in the different samples of tea and herbal infusions as compared to the total concentration in
each of the samples where all the 28 PAs were analysed. Overall, these eight PAs were the main
responsible of the PA levels reported for tea and herbal infusions, with contributions below 60% of the
total in only 25% of the samples of peppermint, in 17% of the samples of camomile, in 14% of the
samples of green tea, in 8% of the samples of black tea and in only 4% of the samples of rooibos.
Bringing the attention to lasiocarpine, one of the most toxic PAs that have been tested (EFSA
CONTAM Panel, 2011), it was analysed in 2,250 of the samples of tea and herbal infusions included in the
ﬁnal data set (96% of the samples). However, this PA was only quantiﬁed in 103 samples (< 5% of the
samples), mostly in samples codiﬁed as ‘Tea and herbs for infusions, unspeciﬁed’ (n = 51) although also
in ‘Tea for infants and young children’ (n = 21). It was in the latter group where lasiocarpine showed the
highest contributions to the total PA concentration, 42% on average, among the 29 samples where this
PA was analysed. In the rest of the samples of tea and herbal infusions, the average contribution of
lasiocarpine was almost negligible, from not being quantiﬁed in any of the samples of black tea to a
maximum average contribution of 1.7% in ‘Tea and herbs for infusions, unspeciﬁed’ (Table 11).
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Having in mind the average contribution of each individual PA to the total PA concentration, it is
important to mention that in four of the data sets, namely MS1-DS, MS2A-DS, MS2B-DS and MS3-DS,
intermedine-N-oxide and lycopsamine-N-oxide are among the PAs that were not analysed. These PAs
have a relatively high contribution to the total concentration of PAs in samples of black tea, on average
30.9% in the case of intermedine-N-oxide (Table 11). As a result, considerable underestimation of the
total concentration of PAs could be expected for the samples of black tea contained in these data sets (70
samples, see Table 10). It is also worth mentioning that in the data set DS-THIE some PAs, with an
important contribution to the total concentration of PAs, were not analysed in a number of samples. As
an example, several herbal infusion samples were not analysed for intermedine-N-oxide (42 samples of
camomile and 37 of unspeciﬁed herbal infusions, among others). Similarly, in 36 samples of camomile,
seneciphylline-N-oxide and lycopsamine (average contribution of ~ 10% and ~ 7%, respectively) were
not analysed, or senecionine-N-oxide that represents in average between 9% and 57% of the total
content of PAs was not analysed in 24 samples of diverse types of tea and herbal infusions. Therefore,
some underestimation when reporting the total concentration of PAs in these samples cannot be
discarded.
Table 11: Average contribution of different PAs to the total PA concentration in the samples of tea
and herbal infusions included in the ﬁnal data set
Unspeciﬁed herbal
infusions, fruit teas and
mixes
Green
tea
Black
tea
Camomile
ﬂowers
Peppermint
Rooibos
leaves
Mean contribution (%)(a)
Echimidine 5.5 1.5 0.0 6.0 0.1 0.2
Echimidine-N-oxide 1.7 0.2 0.0 4.1 1.0 0.5
Erucifoline 0.0 0.0 0.4 0.0 0.4 0.0
Erucifoline-N-oxide 0.3 0.4 0.1 0.0 0.0 0.0
Europine 1.5 0.7 1.4 0.1 0.3 0.0
Europine-N-oxide 19.0 0.2 0.0 0.9 6.1 0.1
Heliotrine 1.4 1.0 0.0 1.4 1.0 0.1
Heliotrine-N-oxide 10.3 0.4 0.4 0.2 5.5 0.2
Intermedine 14.5 16.2 19.6 22.2 0.3 0.4
Intermedine-N-oxide 6.8 4.2 30.9 7.2 0.0 0.7
Jacobine 0.0 2.3 0.9 0.0 0.0 0.0
Jacobine-N-oxide 0.1 3.8 1.8 0.0 0.0 0.0
Lasiocarpine 1.7 1.1 0.0 0.6 0.4 0.0
Lasiocarpine-N-oxide 3.4 0.0 0.2 0.3 1.7 0.2
Lycopsamine 7.5 16.4 19.5 9.5 0.8 0.0
Lycopsamine-N-oxide 5.3 1.6 7.0 5.3 0.8 0.2
Monocrotaline 0.3 0.0 0.0 0.0 0.0 0.1
Monocrotaline-N-oxide 0.2 0.0 0.3 0.0 0.0 0.0
Retrorsine 1.1 1.9 2.3 0.2 1.3 3.2
Retrorsine-N-oxide 6.3 18.2 14.5 4.1 13.1 18.6
seneci(o)phylline 0.9 0.2 0.0 2.7 11.0 0.3
Senecionine 3.9 3.2 1.6 9.9 5.1 14.2
Senecionine-N-oxide 18.7 18.8 9.3 27.5 24.5 56.6
Seneciphylline-N-oxide 2.8 0.4 0.0 7.1 27.8 1.3
Senecivernine 0.4 0.1 0.0 0.9 1.7 1.8
Senecivernine-N-oxide 1.8 0.8 0.5 2.4 0.6 4.4
Senkirkine 1.1 1.7 0.0 1.3 0.1 0.4
Trichodesimine 0.2 0.2 0.0 0.0 0.0 0.0
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Two main analytical methods were used to analyse the samples of tea and herbal infusions
submitted to EFSA: LC–HG–AFS and LC–MS/MS. Table 12 shows the different LOQs reported for each
of the analytical methods used for different data sets. Both methods seem to be able to reach similar
sensitivity in the analysis of PAs; using LC–HG–AFS, an LOQ as low as 0.5 lg/kg was reported for the
analysis of heliotrine. The same LOQ was reported for LC–MS/MS in the analysis of several PAs such as
intermedine, monocrotaline, and senecionine among others.
Despite the high sensitivity that could be reached with both methods, relatively high LOQs were
also reported. In addition, it is also noticed that speciﬁc data sets provided relatively high LOQs for
several or even for all PAs analysed, as observed for instance in the data sets MS1-DS and MS2A-DS.
In other occasions very wide ranges of LOQs were reported for the same PAs using the same
analytical method (e.g. 1.0–45.9 lg/kg for lasiocarpine). A detailed evaluation of the LOQs indicates
that in some speciﬁc data sets, the lowest LOQs for each PA analysed are only reported for very few
samples, while the highest LOQ of the range is reported for most of the analytical results. As an
example, for senecionine, with a LOQ range of 1–20 lg/kg, LOQ = 1 was reported for two analytical
results and LOQ = 10 or 20 reported for 90% of the analytical results. These relatively high LOQs can
lead to scenarios where for different teas and herbal infusions the LB is zero or close to zero and the
UB estimates are rather high, as observed in some of the data sets (Table 10).
Considering the maximum LOQs submitted for the different data sets, in a scenario with all the PAs
submitted as below LOQ, the UB estimates could be as high as 1,340 lg/kg (17.9 lg/L), or 445 lg/kg
(5.9 lg/L) if all PAs were reported as below LOD, in both cases also considering the analytical results
reported as co-eluting PAs. At the same time, considering the two data sets with the minimum LOQs
and reporting all 28 PAs, if all of them were below the LOQ, the minimum UB scenarios would range
between 53 lg/kg (0.7 lg/L) and 98.5 lg/kg (1.3 lg/L).
When comparing the PA concentrations in the different data sets, it can be seen that in general the
concentrations are lower in the data submitted by THIE as compared to the rest of data sets
(Table 10). This is particularly evident when comparing THIE results to the data collected through the
EFSA Article 36 grant (Art36-DS). Although the data set with the oldest samples (MS2A-DS, sampling
years = 2010–2013) showed the highest PA concentrations among the data submitted by the national
authorities, the data submitted through the Art 36 grant contains samples collected between 2014 and
2015 and also showed relatively high concentrations of PAs. In the data sets that contained samples
collected in 2015 (MS1-DS and MS4-DS), the LB estimations for certain food commodities were close
to those estimated for THIE. However, the relatively high UB estimates indicate that the analytical
methods may not be sensitive enough to quantify all the PAs potentially present in the samples.
Unspeciﬁed herbal
infusions, fruit teas and
mixes
Green
tea
Black
tea
Camomile
ﬂowers
Peppermint
Rooibos
leaves
PAs reported as co-eluting
Intermedine/
lycopsamine or
Intermedine/
lycopsamine/indicine
7.5 7.1 12.4 27.6 1.8 0.0
Senecionine/
senecivernine
1.4 0.2 5.0 0.0 0.0 3.1
Senecionine-N-oxide/
senecivernine-N-oxide
43.7 34.0 3.7 0.2 0.0 68.4
Intermedine-N-Oxide/
lycopsamine-N-oxide or
Intermedine-N-oxide/
lycopsamine-N-oxide/
Indicine-N-oxide
11.7 56.9 67.4 2.2 6.7 0.0
Jacobine-N-oxide/
retrorsine-N-oxide
6.9 – – – – 0.0
PA: pyrrolizidine alkaloids.
(a): The average contribution of each PA was estimated in those samples where the PA was analysed and at least one PA was
quantiﬁed.
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In order to cover the whole range of concentrations of PAs reported for tea and herbal infusions,
the estimation of dietary exposure to PAs considered two different scenarios. Together with the other
food commodities, a ﬁrst scenario considered all the samples of tea and herbal infusions submitted by
the national authorities and those collected through the Art 36 grant, while a second scenario took into
account the samples of tea and herbal infusions submitted by THIE.
3.1.3. Food supplements
A ﬁnal number of 278 samples of different food supplements were available in the ﬁnal data set
used to estimate dietary exposure to PAs. The most common number of PAs reported per sample was
28 (n = 193), followed by 19 (n = 78), with the minimum number being 9 for just one sample.
Most of the food supplements were codiﬁed as ‘Plant extract formula’ (n = 200), followed by ‘Pollen-
based supplements’ (n = 41). Some samples of ‘Supplements containing special fatty acids’ (n = 34),
‘Algae formula’ (n = 2) and ‘Enzyme-based supplements’ (n = 1) were also analysed, with all PAs below
the LOQs (Table 13). These three food supplements were not used for exposure estimations.
The concentration of PAs reported for the plant extracts varied enormously. In some of the
supplements codiﬁed as ‘Plant extract formula’ no presence of PAs was reported (e.g. garlic extracts,
ginseng extracts); however, some other supplements possessed relatively high concentrations of PAs.
Among the latter is important to mention diverse supplements containing plant material from
Eupatorium sp., Tussilago farfara (coltsfoot), Borago ofﬁcinalis (borage) and Pulmonaria ofﬁcinalis
(lungwort). Table 14 shows the plant extracts with the highest concentrations (above 25,000 lg/kg),
most of them intended to be consumed as tea infusions. In these samples, the analyses were carried
out in the plant extracts prepared as standard infusions (dilution factor of 1/75, i.e. 2 g in 150 mL),
and the concentrations are also shown in lg/L. The highest average contributions to the total
concentration of PAs came from lycopsamine, intermedine and their N-oxides. An exception was the
samples of coltsfoot, where 80–90% of the total concentration of PAs came from senkirkine.
When both occurrence and consumption data were available for particular plant extracts, they were
included in the general scenarios developed to estimate dietary exposure to PAs; these plant extract
are further detailed in Section 3.2.3. An additional scenario considering those samples with the highest
levels of PAs (Table 13) for which no consumption data are available is also presented in this scientiﬁc
report (Section 4.3).
Table 13: Levels of PAs for different types of food supplements (lg/kg)
N(a) Variable(b) Mean 90th percentile(c) 95th percentile(c)
Supplements containing
special fatty acids
34 LB 0 – –
MB 45 – –
UB 90 – –
Plant extract formula 200 LB 47,110 – 55,459
MB 47,138 – 55,471
UB 47,166 – 55,484
Enzyme-based supplements 1 LB 0 – –
MB 50 – –
UB 100 – –
Algae formula
(e.g. Spirulina, Chlorella)
2 LB 0 – –
MB 101 – –
UB 203 – –
Pollen-based supplements 41 LB 235 967 –
MB 244 970 –
UB 253 974 –
PA: pyrrolizidine alkaloids.
(a): Number of samples.
(b): LB = lower bound; MB = middle bound; UB = upper bound.
(c): 90th and 95th percentile are not shown when the number of samples were lower than 29 and 60, respectively, as they are
not statistically signiﬁcant.
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3.1.4. Other food commodities
Together with the samples described above, a small number of other plant-origin food samples with
measured levels of PAs were available.
There were 13 samples of ‘Processed spinaches’ that reported average values of 0.2 lg/kg at the LB
and 0.9 lg/kg at the UB, with the number of PAs analysed between 8 and 11. Likewise, one sample of
fresh spinach was reported with no levels of PAs detected among the 11 PAs analysed. However, the
average value for the frozen spinaches was imputed to account for the consumption of fresh spinaches.
For 10 samples of unspeciﬁed mixed herbs, either 11 or 16 PAs were analysed. The average levels
were 1.7 lg/kg (LB) and 10 lg/kg (UB), with lycopsamine being the PA more frequently reported, and
at the highest concentration.
Additionally, 39 samples of tea and herbal infusions for children were also submitted with average
values of 0.6 lg/kg (LB) and 1.4 lg/kg (UB). These values were, in general, lower than those for tea
and herbal infusions. Samples were submitted in two different data sets, one with 17 PAs and the
other one with 19 PAs. Among the different PAs, the highest average contribution to the total
concentration came from lasiocarpine (42%) and its N-oxide (14%).
Finally, four samples of ‘Composite food’, vegetable-based meals (spinaches with cream), were
available with 9 and 10 PAs analysed, and average values of 0.05 lg/kg (LB) and 0.8 lg/kg (UB).
3.2. Food consumption data
3.2.1. Consumption of honey
Among the 17,046 eating occasions for honey available in the EFSA consumption database (all
dietary surveys considered, see Appendix A), the vast majority were codiﬁed at FoodEx level 2 as
‘Honey’ without further information (~ 94.5%), with few eating occasions codiﬁed as ‘Honey,
monoﬂoral’ (4%) and ‘Honey polyﬂoral’ (1.5%).
When considering chronic consumption (only dietary surveys with at least 2 days reported), in the
adult population (‘Adults’, ‘Elderly’ and ‘Very elderly’), the percentage of honey consumers varied from 5%
to 50% of the total population, with average chronic consumption ranging from 0.002 to 0.06 g/kg bw
per day and a high chronic consumption (95th percentile) between 0 and 0.32 g/kg bw per day.2 In the
Table 14: Levels of PAs for individual samples of plant extracts (lg/kg)
Type of plant extract(a)
Levels of PAs
Dry product (lg/kg) Infusion (lg/L)(b)
Hemp-agrimony (Eupatorium cannabinum) 2,410,275 –
Boneset (Eupatorium perfoliatum) 1,077,547 –
Borage (Borago ofﬁcinalis) 2,332,558 31,101
Borage (Borago ofﬁcinalis) 2,151,891 28,692
Coltsfoot (Tussilago farfara) 419,309 5,591
Common gromwell (Lithospermum ofﬁcinale) 312,271 4,164
Lungwort (Pulmonaria ofﬁcinalis) 141,401 1,885
Lungwort (Pulmonaria ofﬁcinalis) 129,001 1,720
Coltsfoot (Tussilago farfara) 114,907 1,532
Lungwort (Pulmonaria ofﬁcinalis) 60,295 804
Lungwort (Pulmonaria ofﬁcinalis) 50,624 675
Eupatorium odoratum Linn. Herbal Tea for Health 40,877 545
Comfrey (Symphytum ofﬁcinale L.) 29,694 396
Mix of different herbs (including Pulmonaria ofﬁcinalis) 27,943 373
PA: pyrrolizidine alkaloids.
(a): All plant extracts except the two-ﬁrst (Hemp-agrimony and Boneset) refers to supplements intended to be prepared as tea
infusion. Hemp-agrimony and Boneset are intended to be directly ingested.
(b): Levels of PAs in lg/L were reported for those plant extracts which are intended to be prepared as tea infusion before
consumption; the reported approach was the same as used for tea and herbal infusions (2 g in 150 mL).
2 For the 95th percentile consumption, those dietary surveys with less than 60 honey consumers were not considered as the
number of subjects is not statistically signiﬁcant.
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young population (‘Infants’, ‘Toddlers’ and ‘Other children’), the percentage of honey consumers in the
total population ranged between 1% and 40%. The average chronic consumption varied between 0 and
0.14 g/kg bw per day, and between 0 and 0.49 g/kg bw per day in the high consumers (95th percentile).2
Since honey is a food commodity that is not regularly consumed in the population, the average
consumption values from all participants in the dietary survey are much lower than considering
consumers only. When considering consumers only, in the adult population the average chronic
consumption ranges from 0.01 to 0.27 g/kg bw per day, while in the high consumers (95th
percentile),2 it varied between 0.03 and 0.64 g/kg bw per day.2 In the young population, consumers
only, the average chronic consumption of honey across dietary surveys is between 0.02 and 0.98 g/kg
bw per day, and between 0.05 and 1.13 g/kg bw per day in the high consumers (95th percentile).2
The acute consumption of honey on each individual day was also estimated (consuming days only).
The percentage of days with consumption of honey varied from 2% to 27% in the adult population,
and between 0.3% and 14% in the young population. Across the different dietary surveys, in the adult
population, the average amount of honey consumed considering only the days with honey
consumption was as high as 0.52 g/kg bw per day with a minimum average acute consumption of
0.01 g/kg bw per day. In the adult populations, high consumption (95th percentile)2 varied between
0.05 and 1.22 g/kg bw per day of honey consumption. For the youngest populations, the
corresponding average acute consumption across dietary surveys, considering only consuming days,
ranged between 0.06 and 1.35 g/kg bw per day, while among the high consumers (95th percentile),2
the amounts varied between 0.21 and 1.88 g/kg bw per day.
3.2.2. Consumption of tea and herbal infusions
Among the approximately 118,000 eating occasions for tea and herbal infusions reported in the
EFSA consumption database (all dietary surveys considered), almost 96% were reported as consumed
(liquid). The remaining 4% reported as solid (~ 8,000 eating occasions) were converted into liquid by
multiplying the reported amount by a factor of 75 (~ 2 g in 150 mL of water) before dietary exposure
was estimated. As commented in Section 3.2.1, this factor was selected based on the protocol used in
the EFSA external scientiﬁc report on the occurrence of PAs in food (Mulder et al., 2015).
The different eating occasions were codiﬁed following the same strategy described for the
occurrence data. Around 91,000 eating occasions referred to tea; in about half of the cases
(n = 44,400), it was not speciﬁed whether the consumption referred to green or black tea (‘Tea,
unspeciﬁed’). Since no occurrence data were codiﬁed for ‘Instant tea, liquid’, these eating occasions
and those reported as ice tea-type drinks (ready-to-drink tea) were also recodiﬁed as ‘Tea, unspeciﬁed’
assuming a similar composition in PAs as the standard tea infusions. A great number of eating
occasions were codiﬁed as ‘Black tea, infusion’ (n = 41,000), with around 5,000 reporting the
consumption of ‘Green tea, infusion’. Under the food group ‘Tea and herbs for infusions, unspeciﬁed’
(n = 23,000) were the eating occasions reported as ‘Herbal tea, infusion’ without further information,
those herbal infusions for which occurrence data were not available, and the eating occasions reported
as ‘Fruit tea, infusion’. Among the herbal infusions for which detailed consumption data were reported
were ‘Rooibos’ (n = 2,454), ‘Camomile’ (n = 612) and Peppermint (n = 553).
Chronic consumption of tea and herbal infusions
Table 15 shows the chronic consumption of tea and different herbal infusions across dietary surveys
in Europe for the adult population (‘Adults’, ‘Elderly’ and ‘Very elderly’) and the young population
(‘Infants’, ‘Toddlers’ and ‘Other children’). It can be seen that while in the adult population the highest
percentage of consumers was for the consumption of black tea (up to 94%), in the young population
was for ‘Tea and herbs for infusions, unspeciﬁed’ (up to 83.8%).
The percentage of consumers varied considerably across the different dietary surveys and this had
obviously a clear impact in the range of chronic consumption in the whole population. When looking at
consumers only, the highest mean consumption expressed as mL/kg bw per day was for black tea
(8.7 mL/kg bw per day); among the high consumers, the highest value was for ‘Tea and herbs for
infusions, unspeciﬁed’, with consumption up to 20.8 mL/kg bw per day.
In the young population, for the whole population the mean consumption went up to 5.3 mL/kg bw
per day for ‘Tea, unspeciﬁed’, and up to 23 mL/kg bw per day in the high consumers (for ‘Tea and
herbs for infusions, unspeciﬁed’). Among consumers only, the highest mean consumption reached
30 mL/kg bw per day for ‘Tea and herbs for infusions, unspeciﬁed’ while high consumers reported
consumption up to 40.4 mL/kg bw per day also for the same food category.
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Acute consumption of tea and herbal infusions (consumption days only)
Table 16 shows the acute consumption of tea and herbal infusions in the European population,
divided into adult population (‘Adults’, ‘Elderly’ and ‘Very elderly’) and young population (‘Infants’,
‘Toddlers’ and ‘Other children’). Acute consumption refers to the total consumption of one speciﬁc
commodity in one single day, and it is represented as consumption day.
Among the adult population, the average acute consumption for tea and herbal infusions ranged
between 0.3 mL/kg bw per day for peppermint and 14.5 mL/kg bw per day for ‘Tea and herbs for
infusions, unspeciﬁed’. For the high consumption days (95th percentile), the values varied between
0.1 mL/kg bw per day for ‘Tea and herbs for infusions, unspeciﬁed’ and 32.3 mL/kg bw per day for
‘Tea, unspeciﬁed’
In the young population, the acute mean consumptions ranged from 0.1 mL/kg bw per day for ‘Tea
and herbs for infusions, unspeciﬁed’ to 33.7 mL/kg bw per day for camomile. Among the high
consumption days (95th percentile), the highest value was reported for ‘Tea and herbs for infusions,
unspeciﬁed’ with 64.7 mL/kg bw per day with the lowest value also reported for the same food group
(0.2 mL/kg bw per day).
Table 15: Range of chronic consumption of tea and different herbal infusions across dietary
surveys in Europe for the adult and young population
Consumers
(%)
Whole population
(mL/kg bw per day)
Consumers only
(mL/kg bw per day)
Mean
consumption
95th
consumption(a)
Mean
consumption
95th
consumption(a)
Adult population(b)
Tea and herbs for
infusions, unspeciﬁed
2.6–51.9 0.02–3.4 0.0–14.3 0.03–7.2 0.1–20.8
Tea unspeciﬁed 0.4–69.9 0.0–2.5 0.0–11.3 0.3–7.4 2.0–17.9
Tea unspeciﬁed,
decaffeinated
0.3–10.8 0.0–0.9 0.7 1.5–8.4 21.0
Black tea, infusion 0.7–94.8 0.0–8.3 2.1–18.9 0.5–8.7 4.3–19.0
Green tea, infusion 0.9–12.0 0.02–0.6 0.4–4.3 1.0–6.4 6.4–17.4
Camomile ﬂowers 0.2–21.8 0.0–0.7 3.4 0.5–3.7 10.5
Peppermint 0.03–4.0 0.0–0.1 – 0.1–5.0 –
Rooibos leaves 1.4–13.5 0.03–0.6 0.0–2.8 1.8–5.9 5.4–15.8
Young population(c)
Tea and herbs for
infusions, unspeciﬁed
0.3–83.8 0.0–5.0 0.1–23.0 0.1–30.0 0.1–40.4
Tea unspeciﬁed 0.2–77.5 0.0–5.3 1.9–19.3 0.2–11.3 4.9–31.0
Tea unspeciﬁed,
decaffeinated
0.2–1.1 0.0–0.4 – 1.4–6.6 –
Black tea, infusion 1.6–19.5 0.02–1.2 0.3–6.0 0.4–11.2 12.0–17.4
Green tea, infusion 0.1–1.6 0.0–0.1 – 0.5–4.8 –
Camomile ﬂowers 0.2–4.1 0.0–0.3 – 2.2–8.5 –
Peppermint 0.5–13.3 0.0–0.4 2.9 0.1–4.4 9.1
Rooibos leaves 2.5–6.0 0.1–0.3 – 2.2–11.5 –
Tea for infants and
young children
0.8–29.6 0.0–2.4 – 0.3–17.7 –
bw: body weight.
(a): 95th percentile is not shown when the number of consumers within one speciﬁc survey was lower than 60 as this percentile
is not statistically signiﬁcant.
(b): Adult population includes ‘Adults’, ‘Elderly’ and ‘Very elderly’.
(c): Young population includes ‘Infants’, ‘Toddlers’ and ‘Other children’.
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3.2.3. Consumption of food supplements
A very limited number of eating occasions (n = 1,818) was available for the food supplements for
which analytical results on the presence of PAs was reported (see Table 13), mostly on plant extract
formula (n = 1,786) and few on pollen-based supplements (32 eating occasions). A detailed evaluation
of the consumption data allowed the identiﬁcation of speciﬁc food supplements for which occurrence
data were available. As a result, diverse eating occasions for plant extracts were identiﬁed, some of
them for which all reported data were left-censored (garlic extracts or ginseng extract, among others).
However, several eating occasions of plant extracts with relatively high concentrations of PAs were also
identiﬁed, such as those of St John’s wort (Hypericum perforatum) for which an average value of
1,543 lg/kg was reported (n = 7). Other samples for which both occurrence and consumption data
were available were extracts of the Echinacea sp., sage leaf extracts and artichoke leaf extracts,
among others.
Those plant extracts that were not represented in both the consumption and the occurrence
databases were not considered in the general scenarios developed to estimate dietary exposure to
PAs. However, as mentioned in Section 3.1.3, an additional scenario was carried out to estimate
potential exposure to PAs through the consumption of plant extracts with the highest levels of PAs
(Section 4.3).
Table 16: Range of acute consumption (consumption days only) of tea and different herbal
infusions across dietary surveys in Europe for the adult and young population
Consumption days (%)
Consumption days only (mL/kg bw day)
Mean consumption 95th consumption(a)
Adult population(b)
Tea and herbs for
infusions, unspeciﬁed
1.6–40.7 0.4–14.5 0.1–26.5
Tea unspeciﬁed 0.1–41.3 0.4–10.6 3.9–32.3
Tea unspeciﬁed,
decaffeinated
0.1–8.3 3.0–10.5 23.3
Black tea, infusion 0.3–89.9 3.1–9.5 5.2–19.9
Green tea, infusion 0.5–8.8 2.1–9.3 9.4–22.8
Camomile ﬂowers 0.03–14.2 3.3–5.7 8.3–14.7
Peppermint 0.01–2.0 0.3–10.0 –
Rooibos leaves 0.7–9.7 3.6–9.3 7.9–23.7
Young population(c)
Tea and herbs for
infusions, unspeciﬁed
0.1–64.9 0.1–30.0 0.2–64.7
Tea unspeciﬁed 0.1–58.3 0.4–18.1 9.7–38.2
Tea unspeciﬁed,
decaffeinated
0.1–0.5 3.8–11.7 –
Black tea, infusion 0.5–12.5 0.6–16.8 4.8–43.9
Green tea, infusion 0.04–0.8 2.5–11.3 –
Camomile ﬂowers 0.1–1.0 5.5–33.7 –
Peppermint 0.2–4.5 0.4–13.9 18.2–25.7
Rooibos leaves 1.1–2.3 7.2–25.1 –
Tea for infants and
young children
0.4–15.7 0.1–20.3 42.5–56.6
bw: body weight.
(a): 95th percentile is not shown when the number of consumers within one speciﬁc survey was lower than 60 as this percentile
is not statistically signiﬁcant.
(b): Adult population includes ‘Adults’, ‘Elderly’ and ‘Very elderly’.
(c): Young population includes ‘Infants’, ‘Toddlers’ and ‘Other children’.
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4. Dietary exposure assessment to pyrrolizidine alkaloids
Different dietary exposure scenarios to PAs were considered. Based on the outcome of the 2011
EFSA Scientiﬁc opinion on PAs (EFSA CONTAM Panel, 2011), both acute and chronic exposure were
assessed.
4.1. Chronic dietary exposure
Two main general scenarios were carried out to estimate chronic dietary exposure to PAs. In both
cases, the occurrence data were linked, at the lowest FoodEx level possible, to consumption data from
35 different dietary surveys with at least 2 days assessment (19 different European countries).
In the ﬁrst general scenario, only the occurrence data submitted by national authorities and those
collected through an EFSA Art 36 grant on tea and herbal infusions were considered; these data are
described in Table 10. In the second scenario, data on tea and herbal infusions submitted by THIE were
used. In both scenarios, occurrence data on other food commodities (e.g. honey, food supplements) as
described in Section 3.1 were also considering when estimating dietary exposure to PAs.
4.1.1. Chronic dietary exposure using occurrence data submitted by national
authorities and occurrence data collected through an EFSA Art 36 grant
Table 17 shows the summary statistics of the dietary exposure estimates to PAs when using the
occurrence data on tea and herbal infusions from national authorities and the EFSA Art 36 grant,
together with the other food commodities (honey, food supplements, etc.). Detailed information for
each individual dietary survey and each age class is shown in Appendix C.
The median of the mean estimates across the different dietary surveys were, in general, higher in
the oldest age classes. However, the highest mean dietary exposure in ‘Toddlers’ was 48.4 ng/kg bw
per day (UB), for the age class ‘Very elderly’ went up to 41.8 ng/kg bw per day (UB). The highest
estimates of mean dietary exposure were rather similar in both the youngest age classes (‘Infants’ and
‘Toddlers’) and the oldest age classes (‘Elderly’, ‘Very elderly’).
In the highly exposed population, referring to the 95th percentile of the distribution of the exposure
for each dietary survey and age class, the highest estimates were in ‘Toddlers’ for both LB and UB,
with values of 153.8 ng/kg bw per day and 214.0 ng/kg bw per day, respectively. The highest estimate
of the highly exposed population was also rather high in the age class ‘Infants’. The maximum
exposure estimates for ‘Infants’ and ‘Toddlers’ corresponded to one dietary survey where the main
contributor was ‘Tea and herbs for infusions, unspeciﬁed’, with a contribution at the MB exposure
scenario of 78–85%, (‘Toddlers’-‘Infants’).
Dietary exposure to PAs in speciﬁc groups of the population, namely ‘Pregnant women’ and
‘Lactating women’, were within the range of exposure estimates in the adult population.
Detailed information of the main contributors to the dietary exposure to PA among the different
age classes across dietary surveys is provided as Supplementary electronic information in Appendix F.
Overall, using the MB estimations in ‘Infants’ and ‘Toddlers’, the main average contributors were
either ‘Tea, unspeciﬁed’ or ‘Tea and herbs for infusions, unspeciﬁed’. In ‘Infants’, the contribution of
‘Tea and herbs for infusions, unspeciﬁed’ showed an average contribution up to 98% (median = 43%),
and in ‘Toddlers’, a maximum of 81%, although in more than half of the dietary surveys did not have
any contribution. Regarding ‘Tea, unspeciﬁed’ in ‘Infants’, the maximum contribution was 95%, with no
contribution in four out of six surveys, while in ‘Toddlers’ went up to 96% but with rather low median
contribution (3%). For ‘Toddlers’, honey was, overall, the main contributor (up to 86%) in those
dietary surveys where the consumption of tea and herbal infusion seemed to be secondary. In general,
these dietary surveys were those with the lowest estimates of exposure among ‘Toddlers’.
In the adult population (‘Adults’, ‘Elderly’, ‘Very elderly’), the main contributor to the exposure to
PAs was tea; the consumption of tea in the different dietary surveys was either reported as ‘Tea,
unspeciﬁed’ or as ‘Black tea, infusion’. The maximum average contribution reached up to 99% for ‘Tea,
unspeciﬁed’ while for ‘Black tea, infusion’ went up to 90%. As observed in the young population, the
lowest estimates of exposure were for those dietary surveys where others foods, particularly honey but
also spinaches, became main contributors. Honey was especially important in one country, where its
consumption contributed up to 53% to the total exposure to PAs.
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4.1.2. Chronic dietary exposure using occurrence data submitted by Tea &
Herbal Infusions Europe (THIE)
Table 18 shows the summary statistics of the dietary exposure estimates to PAs by using the
occurrence data on tea and herbal infusions submitted by THIE (Table 9), and the occurrence data
available for other food commodities (honey, food supplements, etc.). Detailed information for each
individual dietary survey and each age class is shown in Appendix D
Overall, the estimates of dietary exposure to PAs using the data from THIE were lower than those
obtained by using the data submitted by national authorities and those collected through the EFSA Art
36 grant. These differences are expected as relatively high differences are observed in the occurrence
data for food commodities that are key contributors to the exposure to PAs, ‘Tea and herbs for
infusions, unspeciﬁed’, ‘Tea, infusion’ and ‘Black tea, infusion’. It is important to note that the differences
in the estimates using the two occurrence data sets decreased for the UB exposure estimates.
Detailed information of the main contributors to the dietary exposure to PA among the different
age classes across dietary surveys is provided as Supplementary electronic information in Appendix F.
Table 17: Summary statistics of chronic dietary exposure assessments to PAs across European
dietary surveys, considering the data on tea and herbal infusions submitted by national
authorities and those collected through an EFSA Art 36 grant(a)
Age class(b) N
Lower bound(d) Upper bound(d)
Min Median Max Min Median Max
Mean dietary exposure (ng/kg bw per day)
Infants 6 0.0 4.1 30.2 0.0 5.9 42.8
Toddlers 10 0.0 3.2 34.5 0.0 5.2 48.4
Other children 18 0.7 4.2 24.1 1.2 6.4 34.3
Adolescents 17 0.3 3.7 18.4 0.6 5.7 26.1
Adults 17 0.2 6.7 21.3 0.4 10.6 28.8
Elderly 14 3.0 8.1 29.5 4.3 12.4 39.9
Very elderly 12 3.9 9.2 31.1 5.7 13.9 41.8
95th percentile dietary exposure(c) (ng/kg bw per day)
Infants 5 0.0 –(e) 133.6 0.0 –(e) 185.2
Toddlers 7 0.0 42.8 153.8 0.0 57.1 214.0
Other children 18 3.3 21.2 90.5 6.3 32.5 125.6
Adolescents 17 0.8 14.6 68.4 2.4 24.6 95.1
Adults 17 1.1 30.1 85.7 2.0 42.9 120.0
Elderly 14 15.3 33.8 87.7 21.4 52.7 123.3
Very elderly 9 15.9 30.8 86.7 22.9 42.8 127.2
bw: body weight; Max: maximum; Min: minimum; N: number of surveys.
(a): Occurrence data on other food commodities (e.g. honey, food supplements) as described in Section 3.1 were also
considered when estimating dietary exposure to PAs.
(b): Section 2.1.2.1 describes the age range within each age class.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b). Those estimates were not included in this table.
(d): Estimates were rounded to one decimal place.
(e): A minimum number of six dietary surveys is required to estimate a statistically robust median (EFSA, 2011b).
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4.1.3. Chronic dietary exposure, consumers only
The standard scenario considering the whole population and the consumption of all commodities is
the most appropriate to reﬂect chronic exposure to hazardous chemicals. However, this scenario could
not be sufﬁcient to protect small subgroups of the population consuming certain foods (e.g. honey) in
a regular basis when these foods present relatively high levels of the chemical under investigation. In
these circumstances, a scenario considering the exposure among consumers only can be useful to
identify possible risks in these subgroups of the population.
When assessing the overall exposure to PAs, tea and herbal infusions are the main sources of
exposure due to their high number of consumers, whereas honey is never appearing as an important
contributor despite the relatively high levels identiﬁed. Considering the relatively high levels of PAs in
honey and its possible regular consumption among consumers only, an ad hoc exposure scenario has
been considered. As result, Tables 19 and 20 shows dietary exposure estimates considering consumers
only, using the two different occurrence data sets that were also used in the general scenarios.
Occurrence data used to estimate exposure are those described in Table 10, while the consumption
data are depicted in Section 3.2. The Tables 19 and 20 show not only the exposure via the
consumption of honey but also for tea and different herbal infusions for which occurrence data are
available in order to show the potential risk associated to their consumption.
Looking at Table 19, in the adult population (‘Adults’, ‘Elderly’, ‘Very elderly’), the mean chronic
exposure via the consumption of honey, among consumers, ranged between 0.1 and 7.4 ng/kg bw per
day (minimum LB–maximum UB), while for high consumers (95th percentile exposure) was between
9.3 and 17.6 ng/kg bw per day (minimum LB–maximum UB). Higher exposure was estimated among
the consumers of honey in the young population (‘Infants’, ‘Toddlers’ and ‘Other children’). For the
average consumers, estimates ranged between 0.3 and 27.0 ng/kg bw per day (minimum
LB–maximum UB), and between 0.7 and 31.1 ng/kg bw per day (minimum LB–maximum UB) among
the high consumers.
Table 18: Summary statistics of chronic dietary exposure assessments to PAs across European
dietary surveys, considering the occurrence data on tea and herbal infusions submitted
by Tea & Herbal Infusions Europe (THIE)(a)
Age class(b) N
Lower bound(d) Upper bound(d)
Min Median Max Min Median Max
Mean dietary exposure (ng/kg bw per day)
Infants 6 0.0 0.6 5..5 0.0 3.6 26.6
Toddlers 10 0.0 1.0 6.1 0.0 4.6 29.8
Other children 18 0.2 1.2 4.4 1.0 5.2 23.7
Adolescents 17 0.2 0.7 3.4 0.5 4.4 18.1
Adults 17 0.1 1.2 3.7 0.4 8.1 22.6
Elderly 14 0.7 1.8 5.4 3.4 9.8 31.6
Very elderly 12 0.9 1.8 5.7 4.3 10.9 33.4
95th percentile dietary exposure(c) (ng/kg bw per day)
Infants 5 0.0 –(e) 19.0 0.0 –(e) 106.2
Toddlers 7 0.0 7.6 23.3 0.0 45.6 131.3
Other children 18 1.3 7.0 14.3 6.3 26.7 77.0
Adolescents 17 0.8 3.7 13.1 2.4 18.5 64.9
Adults 17 0.9 5.4 14.7 1.9 33.7 78.1
Elderly 14 3.0 6.7 14.7 15.9 37.2 78.8
Very elderly 9 4.0 8.2 15.9 18.2 33.9 76.9
bw: body weight; Max: maximum; Min: minimum; N: number of surveys.
(a): Occurrence data on other food commodities (e.g. honey, food supplements) as described in Section 3.1 were also
considered when estimating dietary exposure to PAs.
(b): Section 2.1.2.1 describes the age range within each age class.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b). Those estimates were not included in this table.
(d): Estimates were rounded to one decimal place.
(e): A minimum number of six dietary surveys is required to estimate a statistically robust median (EFSA, 2011b).
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The highest estimates of chronic exposure among consumers only were for ‘Tea and herbs for
infusions, unspeciﬁed’. This is a food category grouping different herbal infusions unspeciﬁed, in few
cases because no occurrence data were available for speciﬁc consumed commodities, but mostly to
the fact that the consumption data were reported without specifying the type of herbal infusion
consumed. Mean exposure estimates up to 228 ng/kg bw per day (UB) in average consumers, and up
to 307 ng/kg bw per day (UB) in high consumers were calculated among the young population.
With the focus on individual types of tea and herbal infusions, the consumption of rooibos seems to
lead, somewhat, to the highest estimates of chronic exposure among consumers only. In the chronic
scenario, the exposure to PAs for the mean consumption of rooibos in the adult population was up to
36.0–41.3 ng/kg bw per day (LB–UB), estimates that were also similar for black tea and peppermint.
Among the high consumers of rooibos, it was up to 96.4–110 ng/kg bw per day (LB–UB). In the young
population, the highest mean exposure also came via the consumption of rooibos (70.2–80.5 ng/kg bw
per day, LB–UB), while in the highest exposure among high consumers was for black tea
(64.4–85.3 ng/kg bw per day, LB–UB). Since the number of consumers of rooibos per dietary survey in
the young population was less than 60, their 95th percentile estimates (high consumers) are not
shown as they are not statistically robust (EFSA, 2011b). Similar conclusions can be extracted looking
at Table 20 (using THIE data) for the food commodities leading to the highest estimates of exposure
among consumers only. For tea and herbal infusions, the estimates were relatively lower based on the
occurrence data used, with lower levels of PAs. This was particularly evident on the exposure
estimation at the LB scenario. The consumption of rooibos led, overall, to the highest estimates of
exposure among consumers only in both the young and the adult population. In the young population,
the highest exposure went up to 66.7 ng/kg bw per day (UB) in the average consumers, while in the
adult population, the highest mean exposure went up to 34.6 ng/kg bw per day (UB) and the highest
95th percentile exposure up to 91.6 ng/kg bw per day.
Table 19: Exposure estimates to PAs across different dietary surveys considering consumers only (Section 3.2), and
the data on tea and herbal infusions submitted by national authorities and those collected through an
EFSA Art 36 grant (Table 10)
Range of chronic dietary exposure (ng/kg bw per day)(d), consumers only
Adult population(a) Young population(b)
Mean exposure 95th exposure(c) Mean exposure 95th exposure(c)
LB UB LB UB LB UB LB UB
Tea and herbs for
infusions,
unspeciﬁed
0.2–39.6 0.2–54.7 0.6–114.4 0.8–158.1 0.6–165.0 0.8–228.0 5.5–222.2 7.6–307.0
Tea, unspeciﬁed 0.9–22.2 1.5–37.0 6.0–53.7 10.0–89.5 0.6–33.9 1.0–56.5 14.7–93.0 24.5–155.0
Tea unspeciﬁed,
decaffeinated
0.5–2.5 2.3–12.6 6.3 31.5 0.4–2.0 2.1–9.9 – –
Black tea,
infusion
1.9–32.2 2.5–42.6 15.9–70.3 21.1–93.1 1.5–41.4 2.0–54.9 44.4–64.4 58.8–85.3
Green tea,
infusion
2.4–15.4 4.8–30.7 15.4–41.8 30.7–83.5 1.2–11.5 2.4–23.0 – –
Camomile
ﬂowers
1.9–14.1 2.7–19.6 39.9 55.7 8.4–32.3 11.7–45.1 – –
Peppermint 0.7–34.0 0.8–42.0 – – 0.7–29.9 0.8–37.0 61.9 76.4
Rooibos leaves 11.0–36.0 12.6–41.3 32.9–96.4 37.8–110.6 13.4–70.2 15.4–80.5 – –
Tea for infants
and young
children
– – – – 0.2–10.6 0.4–24.8 – –
Honey 0.1–3.9 0.3–7.4 0.4–9.3 0.8–17.6 0.3–14.2 0.6–27.0 0.7–16.4 1.4–31.1
bw: body weight; LB: lower bound; UB: upper bound.
(a): Adult population comprises the age classes ‘Adults’, ‘Elderly’ and ‘Very elderly’ across the different dietary surveys.
(b): Young population comprises the age classes ‘Infants’, ‘Toddlers’ and ‘Other children’ across the different dietary surveys.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA,
2011b). Those estimates were not included in this table.
(d): Estimates were rounded to one decimal place.
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4.2. Acute dietary exposure, consumption days only
Acute dietary exposure to PAs was estimated following a conservative approach considering the
presence of high contamination levels in all the different food commodities (occurrence values at the
highest reliable percentile,3 UB estimate), combined with the total daily consumption amount for each
corresponding food (consuming days only). A total of 41 different and most recent dietary surveys
carried out in 23 different European countries were used.
In comparison to the previous Section 4.1, where chronic consumption in consumers only was
estimated separately for different foods to identify possible risks in small subgroups of the population
that consume these foods on a regular basis (e.g. honey), this scenario estimates the exposure adding
up all consumed foods during one single day. Estimations of acute dietary exposure were carried out
using the occurrence data set generated with the data submitted by national authorities and those
collected through an EFSA Art 36 grant. The highest reliable percentile (UB estimate) for the most
important food commodities were as follows: ‘Black tea infusion’ (95th percentile = 18 lg/L), ‘Green
tea, infusion’ (95th percentile = 14.4 lg/L), ‘Camomile ﬂowers’ (95th percentile = 16.2 lg/L),
‘Peppermint’ (95th percentile = 13.2 lg/L), ‘Rooibos leaves’ (95th percentile = 15.4 lg/L), ‘Tea and
herbs for infusions, unspeciﬁed’ (95th percentile = 16.3 lg/L) and ‘Tea, unspeciﬁed’ (95th
percentile = 15.4 lg/L).
Table 21 shows the summary statistics of the acute exposure to PAs among consuming days only
(UB estimates). Highest estimates of acute mean exposure and 95th percentile exposure were
calculated for ‘Toddlers’, with mean acute exposure to PAs up to 310.8 ng/kg bw per day and 95th
percentile exposure up to 820.5 ng/kg bw per day.
Table 20: Exposure estimates to PAs across different dietary surveys considering consumers only (Section 3.2) and
the occurrence data on tea and herbal infusions submitted by Tea & Herbal Infusions Europe (THIE)
(Table 10)
Range of chronic dietary exposure (ng/kg bw per day)(d), consumers only
Adult population(a) Young population(b)
Mean exposure 95th exposure(c) Mean exposure 95th exposure(c)
LB UB LB UB LB UB LB UB
Tea and herbs for
infusions, unspeciﬁed
0.0–4.3 0.1–31.0 0.1–12.5 0.4–89.4 0.1–18.0 0.4–129.0 0.6–24.2 4.3–173.7
Tea, unspeciﬁed 0.2–3.7 1.1–28.1 1.0–9.0 7.6–68.0 0.1–5.7 0.8–42.9 2.5–15.5 18.6–117.8
Tea unspeciﬁed,
decaffeinated
– 4.4–24.4 – 60.9 0.0–0.0 4.1–19.1 – –
Black tea, infusion 0.3–5.2 2.0–33.9 2.6–11.4 16.8–74.1 0.2–6.7 1.6–43.7 7.2–10.4 46.8–67.9
Green tea, infusion 0.3–1.9 3.6–23.0 1.9–5.2 23.0–62.6 0.2–1.4 1.8–17.3 – –
Camomile ﬂowers 0.5–3.7 2.2–15.9 10.5 45.2 2.2–8.5 9.5–36.6 – –
Peppermint 0.6–6.0 2.4–23.5 – – 0.1–5.3 0.5–20.7 10.9 42.8
Rooibos leaves 4.9–15.9 10.4–34.2 14.6–42.7 31.3–91.6 5.9–31.1 12.8–66.7 – –
PA: pyrrolizidine alkaloid; bw: body weight; LB: lower bound; UB: upper bound.
(a): Adult population comprises the age classes ‘Adults’, ‘Elderly’ and ‘Very elderly’ across the different dietary surveys.
(b): Young population comprises the age classes ‘Infants’, ‘Toddlers’ and ‘Other children’ across the different dietary surveys.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust
(EFSA, 2011b). Those estimates were not included in this table.
(d): Estimates were rounded to one decimal place.
3 The selection of the highest reliable percentiles was based on the number of samples available, 60 samples for the 5th and
95th percentile, 11 samples for 25th and 75th percentile, and six samples for the median. Otherwise, the percentiles may not
be statistically robust.
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As observed for the estimates of chronic dietary exposure, using the occurrence data set from THIE
results in lower acute exposure estimates as compared to those described in Table 21. Highest
estimates of acute mean exposure and 95th percentile exposure were also calculated for ‘Toddlers’,
with mean acute exposure to PAs up to 147.8 ng/kg bw per day and 95th percentile exposure up to
413.8 ng/kg bw per day.
4.3. Dietary exposure through the consumption of plant extracts and
pollen-based supplements
The occurrence data reported for ‘Plant extracts’ were diverse and with a wide range of
concentrations of PAs. When there were available consumption data, exact linking was made with the
occurrence data, and the plant extracts were included in the general scenarios of exposure. However,
for several of the plant extracts with PAs levels, no speciﬁc consumption data were available so they
were excluded to avoid introducing uncertainty in the exposure estimation. Some of these plant
extracts featured very high levels of PAs as compared to the levels reported for tea and herbal
infusions (see Table 14), and their consumption, therefore, could lead to high exposure to PAs.
In the absence of consumption data, the potential exposure from the plant extracts intended to be
consumed as infusions was estimated using a single consumption of 150 mL infusion of 2 g of plant
extract (dilution factor 1/75 as used for tea and herbal infusions). With this consumption, the
estimated exposure to PAs via this particular plant extracts would range between 800 ng/kg bw per
day for one sample of mix herbs, among them Pulmonaria ofﬁcinalis, and 67,000 ng/kg bw per day for
one sample of Borage (Borago ofﬁcinalis). Likewise, for two samples of plant extracts reported to be
ingested directly (as capsules/tablets), the consumption of 1 unit (standard weight 0.75 g) would imply
exposure to PAs of 808,160 ng/kg bw per day for Boneset (Eupatorium perfoliatum) and
1,807,706 ng/kg bw per day for Hemp-agrimony (Eupatorium cannabinum).
Regarding pollen-based supplements, as commented in the consumption section, only 32 eating
occasions are available in the consumption database. Based on these data and the reported occurrence
data, some rough estimations of the exposure to PAs via the consumption of pollen-based supplements
were done. For chronic consumption, using the occurrence value, the reported mean concentration
(LB = 235 lg/kg, UB = 253 lg/kg), the chronic exposure would range between 0.7 and 11.5 ng/kg bw
per day (minimum LB–maximum UB) among consumers only. The acute exposure, using as occurrence
value the highest reliable percentile (LB-P90 = 966 lg/kg, UB-P90 = 974 lg/kg), would be between 2.8
and 43.9 ng/kg bw per day (minimum LB–maximum UB) among consumers only.
Table 21: Summary statistics of acute dietary exposure to PAs (consumption days only) considering
the data on tea and herbal infusions submitted by national authorities and those
collected through an EFSA Art 36 grant (occurrence values at the highest reliable
percentile, UB estimate)
Age class(d)
Acute dietary exposure (ng/kg bw per day, consumption days only)(a),(b)
Upper bound estimations
Mean exposure 95th percentile dietary exposure(c)
N Min Median Max N Min Median Max
Infants 6 1.2 98.7 212.8 5 154.1 –(e) 719.7
Toddlers 10 1.7 109.6 310.8 7 261.8 419.4 820.5
Other children 18 19.6 88.2 248.1 18 125.5 276.6 505.1
Adolescents 17 8.9 71.5 151.5 17 90.4 194.5 415.0
Adults 17 5.8 86.8 159.9 17 22.4 226.4 495.5
Elderly 14 29.2 76.7 161.9 14 81.5 234.2 388.9
Very elderly 12 33.1 84.1 168.1 9 110.4 218.1 382.8
PA: pyrrolizidine alkaloid; bw: body weight; Max: maximum; Min: minimum; N: number of surveys.
(a): Occurrence data on other food commodities (e.g. honey, food supplements) as described in Section 3.1 were also
considered when estimating acute dietary exposure to PAs.
(b): Estimates were rounded to one decimal place.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b). Those estimates were not included in this table.
(d): Section 2.1.2.1 describes the age range within each age class.
(e): A minimum number of six dietary surveys is required to estimate a statistically robust median (EFSA, 2011b).
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4.4. Potential dietary exposure at hypothetical PAs concentrations
The inﬂuence on the dietary exposure to PAs when consuming particular food commodities with
selected concentrations was assessed. These concentrations were based on the performance of the
reported analytical methods and, when possible, on the distribution of the reported occurrence data.
The targeted food commodities were tea, herbal infusions and honey, all of them key contributors to
the exposure to PAs.
As commented above, the most recent data seems to indicate somehow lower levels of PAs in
different teas and herbal infusions as compared to the samples collected in the previous years
(Table 10). However, this is more evident at the LB scenario which opens the possibility that this trend is
not due to a decrease in the levels but rather to differences in the sensitivity of the applied methods.
Sensitive analytical methods are required to avoid situations where LB scenarios are zero or close to
zero, while the UB scenarios show relatively high concentrations of PAs. Considering the two studies that
analysed the 28 PAs and reported the lowest LOQs (see Table 12), if all PAs were at levels below the
LOQ, the UB scenario for the total concentration of PAs would be between 53 and 98.5 lg/kg in the dry
product (0.7 lg/L and 1.3 lg/L in the prepared infusions). Regarding honey, and with the focus on the
samples that reported the data set of 8 PAs described in Section 3.1.1, the lowest UB concentration that
could be reported for a sample of honey with the eight PAs below the LOQ would be 3.6 lg/kg.
Table 22 shows the estimations of exposure among consumers only of tea and herbal infusion, and
among consumers of honey only when chronic consumption data are combined with minimum UB
concentrations that could be reported for these food commodities based on the sensitivity of the
analytical methods. Additional chronic exposure estimations, also for honey consumers only, were
carried out assuming a concentration of 5 lg/kg based on the median concentration (LB) among all
reported samples of honey.
For tea and herbal infusions, based on the current sensitivity of the reported analytical methods for
28 PAs, UB concentrations below 53 lg/kg (0.7 lg/L) cannot be excluded, what implies mean
exposure levels in the young population up to 21.0 ng/kg bw per day and up to 28.3 ng/kg bw per
day among the highly exposed consumers, in both cases for consumers only of ‘Tea and herbs for
infusion, unspeciﬁed’ (for more details see Table 22).
The chronic consumption of honey, at hypothetical PA concentrations of 3.6–5 lg/kg, led to
maximum mean exposure estimations among consumers that ranged between 3.5 and 4.9 ng/kg bw
per day, and between 1.0 and 1.4 ng/kg bw per day, in the adult and young population, respectively.
For the same PA concentrations, the highest exposures among high consumers of honey ranged
between 2.3 and 3.2 ng/kg bw per day, and between 4.1 and 5.7 ng/kg bw per day in the adult and
young population, respectively.
Table 22: Chronic exposure estimates to PAs across different dietary surveys considering
consumers only and selected concentrations of PAs in different food commodities as
described in the text
Concentration of
PAs (lg/L)
Young population(a) Adult population(b)
Mean
exposure
95th
exposure(c)
Mean
exposure
95th
exposure(c)
ng/kg bw per day(d) ng/kg bw per day(d)
Tea and herbs for
infusions, unspeciﬁed
0.7 0.1–21.0 0.7–28.3 0.0–5.0 0.1–14.6
Tea unspeciﬁed 0.7 0.1–7.9 3.4–21.7 0.2–5.2 1.4–12.5
Tea unspeciﬁed,
decaffeinated
0.7 1.0–4.6 – 1.1–5.9 14.7
Black tea, infusion 0.7 0.3–7.8 8.4–12.2 0.4–6.1 3.0–13.3
Green tea, infusion 0.7 0.4–3.4 – 0.7–4.5 4.5–12.2
Camomile ﬂowers 0.7 1.5–6.0 – 0.4–2.6 7.4–7.4
Peppermint 0.7 0.1–3.1 6.4–6.4 0.1–3.5 –
Rooibos leaves 0.7 1.5–8.1 – 1.3–4.1 3.8–11.1
Tea for infants and
young children
0.7 0.2–12.4 – – –
Honey 3.6(e) 0.1–3.5 0.2–4.1 0.0–1.0 0.1–2.3
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5. Uncertainty
A qualitative evaluation of the inherent uncertainties in the assessment of the dietary exposure to
PAs was performed following the guidance of the Opinion of the Scientiﬁc Committee related to
Uncertainties in Dietary Exposure Assessment (EFSA, 2006).
Considering the relevant 28 PAs provisionally selected by the European Commission, a ﬁnal data set
of 4,581 samples of plant origin was available for exposure estimations. The total content of PAs in
each food sample was estimated adding up the reported amount for each individual PA analysed. To
avoid underestimation on the presence of PAs, only those samples with a minimum number of PAs
were included in the ﬁnal data set; this number was selected after a comprehensive evaluation of the
occurrence data in each type of food commodity. As there were samples in the ﬁnal data set that did
not contain analytical data for all 28 PAs, this may cause some underestimation in the dietary exposure
to PAs.
A total of 1,002 samples were codiﬁed as ‘Tea and herbs for infusions, unspeciﬁed’. This food
category covers a very heterogeneous group of samples that includes mix of herbal infusions, mixes of
tea and herbal infusions, unspeciﬁed herbal infusions, and herbal infusions that could not be classiﬁed
under FoodEx. This adds uncertainty to the estimations of exposure via the consumption of ‘Tea and
herbs for infusions, unspeciﬁed’.
The large proportion of left-censored data introduces uncertainty to the overall dietary exposure
estimates. In total, 90% of the analytical results were left-censored, and for 40% of the samples, the
levels for all measured PAs were left-censored. This is particular important in this case as the
concentration of PAs in the samples is the result of adding up the individual levels of up to 28 PAs. In
this situation, the reported LOQ has a large inﬂuence on the calculation of the UB levels, and large
variances in LOQs were seen for the different analytical methods. While the LB values tend to
underestimate the estimations of dietary exposure to PAs, UB values tend to overestimate it.
Uncertainty is also associated to how accurately the concentration of PAs reported in the samples
of tea and herbal infusions represents the amounts of contaminants the consumers are exposed to.
Different methods are used to extract the PAs present in tea and herbal infusions previous to their
analysis, and there is uncertainty on how these methods represent the different ways the consumers
use to prepare tea and herbal infusions. In addition, many different factors, such as water
temperature, water-to-tea ratio, infusion time, stirring, and dosage form (loose leaf and tea bag), may
have inﬂuence on the extraction of PAs during consumer preparation.
Concentration of
PAs (lg/L)
Young population(a) Adult population(b)
Mean
exposure
95th
exposure(c)
Mean
exposure
95th
exposure(c)
ng/kg bw per day(d) ng/kg bw per day(d)
Tea and herbs for
infusions, unspeciﬁed
1.3 0.1–39.0 1.3–52.5 0.0–9.4 0.1–27.0
Tea unspeciﬁed, 1.3 0.3–14.7 6.4–40.3 0.4–9.6 2.6–23.3
Tea unspeciﬁed,
decaffeinated
1.3 1.8–8.6 – 2.0–10.9 27.3
Black tea, infusion 1.3 0.5–14.6 15.6–22.6 0.7–11.3 5.6–24.7
Green tea, infusion 1.3 0.7–6.2 – 1.3–8.3 8.3–22.6
Camomile ﬂowers 1.3 2.9–11.1 – 0.7–4.8 13.7
Peppermint 1.3 0.1–5.7 11.8–11.8 0.1–6.5 –
Rooibos leaves 1.3 2.9–15.0 – 2.3–7.7 7.0–20.5
Tea for infants and
young children
1.3 0.4–23.0 – – –
Honey 5(e) 0.1–4.9 0.3–5.7 0.1–1.4 0.2–3.2
PA: pyrrolizidine alkaloid; bw: body weight.
(a): Young population comprises the age classes ‘Infants’, ‘Toddlers’ and ‘Other children’ across the different dietary surveys.
(b): Adult population comprises the age classes ‘Adults’, ‘Elderly’ and ‘Very elderly’ across the different dietary surveys.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b). Those estimates were not included in this table.
(d): Estimates were rounded to one decimal place.
(e): The concentration of PAs in honey refers to lg/kg.
Pyrrolizidine alkaloids exposure assessment
www.efsa.europa.eu/efsajournal 37 EFSA Journal 2016;14(8):4572
Uncertainties and limitations related to the use of the EFSA Comprehensive Food Consumption
Database have already been described in EFSA (EFSA, 2011b) and are not further detailed; only those
with a particular repercussion on the dietary exposure to PAs are mentioned here. Among them is the
consumption data on tea and herbal infusions reported as unspeciﬁed (~ 55% considering all dietary
surveys), either as ‘Tea and herbs for infusions, unspeciﬁed’ or ‘Tea, unspeciﬁed’. The latter food
category includes, among others, many eating occasions of ready-to-drink tea (ice tea-type drinks)
that may possess variable amount of tea in its composition (Section 3.2.2). This adds uncertainty also
to the estimations of exposure via the consumption of ‘Tea, unspeciﬁed’ together with the above
mentioned uncertainty coming via the consumption of ‘Tea and herbs for infusions, unspeciﬁed’
(Table 23).
Overall, the dietary exposure to PAs calculated in this report is likely to overestimate the exposure
levels of the European population.
6. Conclusions
• Based on the different data sets reported, for tea and herbal infusions, samples with a minimum
of 17 and a maximum of 28 analysed PAs were selected to estimate dietary exposure to PAs.
• For honey, the number of PAs per sample in the ﬁnal data set varied between 8 and 19, based
on the common PAs reported in all the samples used in the EFSA 2011 opinion, and the
recently reported samples analysed for at least echimidine, lycopsamine, and senecionine.
• Among the samples of retail honey, the main contributors to the total PA concentration in each
sample were, on average, echimidine (44%) and lycopsamine (37%).
• Among the samples of tea and herbal infusions, the main contributors to the total PA
concentration were, on average: lycopsamine, intermedine, intermedine-N-oxide, senecionine,
senecionine-N-oxide, seneci(o)phylline, seneciphylline-N-oxide, and retrorsine-N-oxide.
• Taking into account the ﬁnal data set, in black tea these eight PAs represented, on average,
95% of the total PA concentration, 92% in samples of rooibos, 90% in samples of camomile,
83% in samples of peppermint and 78% in green tea.
• Looking at the contribution of these eight PAs as compared to the 28 PAs in those samples
where all 28 PAs were analysed, similar average contributions were observed, with
contributions below 60% of the total, in only 25% of the samples of peppermint, in 17% of
the samples of camomile, in 14% of the samples of green tea, in 8% of the samples of black
tea and in only 4% of the samples of rooibos.
• An apparent downwards trend was noted in the levels of PAs in tea and herbal infusions,
based on some of the most recently reported levels. This is observed, in particular, at the LB
scenario, indicating that this trend may be inﬂuenced by the lack of sensitivity of the analytical
methods.
Table 23: Summary of the qualitative evaluation of the impact of uncertainties on the dietary
exposure to PAs
Sources of uncertainty Direction(a)
Measurement uncertainty of analytical results associated to the methods of analysis 
Using the substitution method at the lower bound (LB) scenario 
Using the substitution method at the upper bound (UB) scenario +
Samples in the ﬁnal data set that did not contain analytical data for all 28 PAs 
Representativity of occurrence data to the whole of Europe 
High number of samples reported as ‘Tea and herbs for infusions, unspeciﬁed’ 
Eating occasions of ready-to-drink tea (ice tea-type drinks) all classiﬁed as ‘Tea, unspeciﬁed’ +
High number of eating occasions on tea and herbal infusions reported as unspeciﬁed (‘Tea and
herbs for infusions, unspeciﬁed’ or ‘Tea, unspeciﬁed’)

Extrapolation of analytical methods to the domestic preparation of tea and herbal infusions 
Variability on the domestic preparation of tea and herbal infusions 
Estimation of acute dietary exposure using occurrence values at the highest reliable percentile
(UB estimate) for all foods
+
(a): + = uncertainty with potential to cause over-estimation of exposure;  = uncertainty with potential to cause underestimation
of exposure.
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• Considering all food commodities, and the data on tea and herbal infusions submitted by MS
and through an EFSA Article 36 grant, the highest estimates of mean chronic dietary exposure
to PAs in the young population (‘Infants’, ‘Toddlers’ and ‘Other children’) were 34.5–48.4 ng/kg
bw per day (LB–UB) and 31.1–41.8 ng/kg bw per day (LB–UB) in the adult population
(‘Adults’, ‘Elderly’, ‘Very elderly’). In the highly exposed population, the highest estimates were
153.8–214.0 ng/kg bw per day and 87.7–127.2 ng/kg bw per day (LB–UB) in the young and
the adult population, respectively.
• When using the data on tea and herbal infusions submitted by Tea & Herbal Infusions Europe
(THIE), the estimates of chronic exposure were lower as compared to the previous scenario.
The highest estimates of mean chronic dietary exposure to PAs in the young population
(LB–UB) were 6.1–29.8 ng/kg bw per day and 5.7–33.4 ng/kg bw per day in the adult
population. In the highly exposed population, the highest estimates were 23.3–131.6 ng/kg bw
per day and 15.9–78.8 ng/kg bw per day (LB–UB) in the young and the adult population,
respectively.
• Overall, in ‘Infants’ and ‘Toddlers’, the main average contributors were either ‘Tea, unspeciﬁed’
or ‘Tea and herbs for infusions, unspeciﬁed’. In the adult population, the main contributor to
the exposure to PAs was tea; either reported as ‘Tea, unspeciﬁed’ or as ‘Black tea, infusion’.
• In the adult population, the mean chronic exposure via the consumption of honey, among
consumers only, ranged between 0.1 and 7.4 ng/kg bw per day (minimum LB–maximum UB),
while for high consumers (95th percentile exposure), it was between 9.3 and 17.6 ng/kg bw
per day (minimum LB–maximum UB). In the young population, for the average consumers
estimates ranged between 0.3 and 27.0 ng/kg bw per day (minimum LB–maximum UB), and
between 0.7 and 31.1 ng/kg bw per day (minimum LB–maximum UB) among the high
consumers.
• The highest estimates of acute mean and high (95th percentile) exposure were calculated for
‘Toddlers’, being up to 311 ng/kg bw per day and up to 821 ng/kg bw per day, respectively.
• The consumption of 150 mL infusion of 2 g of certain plant extracts with relatively high PA
levels can lead to exposure to PAs from 800 ng/kg bw per day for one infusion of mixed herbs
to 67,000 ng/kg bw per day for one infusion of Borage.
• Chronic exposure to PAs via the consumption of pollen-based supplements ranged between 0.7
and 11.5 ng/kg bw per day (minimum LB–maximum UB), while the acute exposure was
between 2.8 and 43.9 ng/kg bw per day (minimum LB–maximum UB) in both cases among
consumers only.
• On estimating dietary exposure to 28 PAs, the UB scenario is highly inﬂuenced by the
sensitivity of the analytical methods. Based on the current sensitivity of the reported analytical
methods, lowest UB concentrations of 53 lg/kg (0.7 lg/L) can be achieved for tea and herbal
infusions. This implies mean chronic exposure levels up to 6.1–21.0 ng/kg bw per day, and up
to 14.6–28.3 ng/kg bw per day among the highly exposed consumers (adult–young
population), depending on the tea and herbal infusion consumed.
• For honey, the lowest UB concentration that could be reported with all eight PAs at levels
below the LOQ would be 3.6 lg/kg. This would lead to mean chronic exposure estimations up
to 3.5 ng/kg bw per day and up to 4.1 ng/kg bw per day among the highly exposed
consumers.
Recommendations
• To develop more sensitive analytical methods allowing the reduction in UB levels, and deﬁne
performance criteria for the analysis of the most relevant PAs in food. Alternatively, to identify
the most relevant PAs in the different food commodities to be included in the UB scenario.
• To continue ongoing efforts to collect analytical data on the occurrence of PAs in relevant food
commodities such as honey, but in particular on tea and herbal infusions (including ‘Tea for
infants and young children’) to conﬁrm the downwards trend in PA levels on the most recently
reported samples.
• Data on the occurrence of PAs in herbal food supplements other than plant extracts should be
collected.
• To obtain information on the sources of PAs in tea, i.e. the weeds responsible for the
contamination and develop adequate measures to control weed infestation.
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Appendix B – Levels of pyrrolizidine alkaloids in the dry product (µg/kg)
for different types of tea and herbal teas
Table B.1: Levels of pyrrolizidine alkaloids in the dry product (µg/kg) of different types of tea and
herbal teas, and samples of ‘Tea for infants and young children’
N(a) Variable Mean
Percentiles(b),(c)
P5 P25 Median P75 P95
Tea and herbal teas
Tea and herbs for infusions,
unspeciﬁed
1,002 Lower bound 133 0 0 0 61 408
Middle bound 257 67 130 140 230 478
Upper bound 381 134 260 270 380 580
Tea, unspeciﬁed 14 Lower bound 70 – 0 10 108 –
Middle bound 293 – 230 237 328 –
Upper bound 515 – 460 465 548 –
Tea, decaffeinated 12 Lower bound 11 – 0 0 14 –
Middle bound 93 – 55 90 123 –
Upper bound 174 – 102 132 241 –
Black tea, infusion 339 Lower bound 116 0 0 0 39 568
Middle bound 216 50 88 130 181 669
Upper bound 315 95 148 260 287 770
Green tea, infusion 310 Lower bound 57 0 0 0 12 276
Middle bound 172 47 130 130 173 317
Upper bound 287 61 250 260 282 460
Camomile ﬂowers 256 Lower bound 173 0 0 29 165 735
Middle bound 265 20 110 147 293 778
Upper bound 358 35 207 270 432 836
Peppermint 196 Lower bound 263 0 0 31 119 766
Middle bound 365 54 135 152 230 827
Upper bound 467 100 218 270 372 887
Hibiscus ﬂowers 6 Lower bound 1 – – 0 – –
Middle bound 154 – – 179 – –
Upper bound 306 – – 358 – –
Rose petals 1 Lower bound 0 – – – – –
Middle bound 110 – – – – –
Upper bound 220 – – – – –
Lime (linden) 1 Lower bound 0 – – – – –
Middle bound 223 – – – – –
Upper bound 445 – – – – –
Rooibos leaves 167 Lower bound 305 0 84 169 330 774
Middle bound 388 50 166 274 403 799
Upper bound 471 89 270 384 499 845
Yerba mate 3 Lower bound 32 – – – – –
Middle bound 162 – – – – –
Upper bound 292 – – – – –
Fruit juice and herbal tea for infants and young children
Tea for infants and young children 39 Lower bound 47 – 0 16 71 –
Middle bound 75 – 9 61 120 –
Upper bound 103 – 13 87 163 –
(a): Number of samples.
(b): P5/P25/75/95: 5th/25th/50th/75th/95th percentiles.
(c): The estimation of high percentiles is not reliable when too few observations are available (less than 11 for the P75, 29 for
the P90, 60 for the P95 and 298 for the P99).
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Appendix E – Percentage of contribution of eight selected PAs as compared
to the total PA concentration in tea and herbal infusions
Appendix E can be found in the online version of this output (‘Supporting information’ section):
http://dx.doi.org/10.2903/j.efsa.2016.4572
www.efsa.europa.eu/efsajournal 49 EFSA Journal 2016;14(8):4572
Pyrrolizidine alkaloids exposure assessment
Appendix F – Contribution of different foods to chronic dietary exposure to
pyrrolizidine alkaloids
Appendix F can be found in the online version of this output (‘Supporting information’ section):
http://dx.doi.org/10.2903/j.efsa.2016.4572
www.efsa.europa.eu/efsajournal 50 EFSA Journal 2016;14(8):4572
Pyrrolizidine alkaloids exposure assessment
